# Tissue adhesives for traumatic lacerations in children and adults (Review)

Farion KJ, Russell KF, Osmond MH, Hartling L, Klassen TP, Durec T, Vandermeer B



This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2009, Issue 1

http://www.thecochranelibrary.com



# TABLE OF CONTENTS

IEADER	1
BSTRACT	1
LAIN LANGUAGE SUMMARY	2
ACKGROUND	2
DBJECTIVES	3
ΛΕΤΗΟDS	3
ESULTS	5
DISCUSSION	8
UTHORS' CONCLUSIONS	10
CKNOWLEDGEMENTS	10
EFERENCES	11
CHARACTERISTICS OF STUDIES	14
DATA AND ANALYSES	23
Analysis 1.1. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 1 Cosmesis (CVAS) at 5 to 14	
days	26
Analysis 1.2. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 2 Cosmesis (CVAS) at 1 to 3	
months	27
Analysis 1.3. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 3 Cosmesis (CVAS) at 9 to 12	
months	28
Analysis 1.4. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 4 Cosmesis (WES, Other) at 5 to	
14 days	28
Analysis 1.5. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 5 Cosmesis (WES, Other) at 1 to	
3 months	29
Analysis 1.6. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 6 Cosmesis (WES, Other) at 9 to	
12 months	29
Analysis 1.7. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 7 Cosmesis (CVAS) at 5 to 14 days	
by age	30
Analysis 1.8. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 8 Cosmesis (CVAS) at 1 to 3	
months by age	30
Analysis 1.9. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 9 Cosmesis (CVAS) at 9 to 12	
months by age	31
Analysis 1.10. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 10 Cosmesis (WES, Other) at 5	
to14 days by age	32
Analysis 1.11. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 11 Cosmesis (WES, Other) at 1	
to 3 months by age	33
Analysis 1.12. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 12 Cosmesis (WES, Other) at 9	
to 12 months by age	34
Analysis 1.14. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 14 Cosmesis (CVAS) at 1 to 3	
months by location	35
Analysis 1.15. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 15 Cosmesis (CVAS) at 9 to 12	
months by location	35
Analysis 1.16. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 16 Cosmesis (WES, Other) at 5	
to 14 days by location	36
Analysis 1.17. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 17 Cosmesis (WES, Other) at 1	
to 3 months by location	37
Analysis 1.18. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 18 Cosmesis (WES, Other) at 9	
to 12 months by location.	38
Analysis 1.20. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 20 Cosmesis (CVAS) at 1 to 3	
months by deep sutures	39
Analysis 1.21. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 21 Cosmesis (CVAS) at 9 to 12	
months by deep sutures.	40
issue adhesives for traumatic lacerations in children and adults (Review)	i

Analysis 1.24. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 24 Cosmesis (WES, Other) at 9       41         Analysis 1.25. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 25 Cosmesis (CVAS) at 1 to 3       42         Analysis 1.26. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 26 Cosmesis (CVAS) at 1 to 3       42         Analysis 1.27. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 27 Cosmesis (CVS) at 9 to 12       42         Analysis 1.27. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 27 Cosmesis (CVS) at 9 to 12       44         Analysis 1.28. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 28 Cosmesis (WES, Other) at 1       44         Analysis 1.29. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 28 Cosmesis (WES, Other) at 1       45         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 9       46         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (min).       48         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Complications.       49         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Complete (min).       48         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outco	Analysis 1.23. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 23 Cosmesis (WES, Other) at 1 to 3 months by deep sutures.	41
Analysis 1.25. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 25 Cosmesis (CVAS) at 5 to 14       42         Analysis 1.26. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 26 Cosmesis (CVAS) at 1 to 3       42         Analysis 1.27. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 27 Cosmesis (CVS) at 9 to 12       43         Analysis 1.27. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 28 Cosmesis (WES, Other) at 5       44         Analysis 1.28. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at 1       46         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at 9       46         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 9       46         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (min).       48         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Ease of Procedure (VAS).       49         Analysis 2.12. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Complications.       49         Analysis 1.33. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Complications.       49         Analysis 2.12. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (oct	Analysis 1.24. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 24 Cosmesis (WES, Other) at 9	61
days by tissue adhesive.       42         Analysis 1.26. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 26 Cosmesis (CVS) at 9 to 12       42         Manalysis 1.27. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 27 Cosmesis (CVS) at 9 to 12       43         Manalysis 1.28. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 28 Cosmesis (WES, Other) at 5       44         Analysis 1.29. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at 1       45         Analysis 1.29. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 1       45         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 9       46         Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Pain (VAS).       47         Analysis 1.33. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       48         Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       48         Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Pain (VAS).       49         Outcome 1 Cosmesis (CVAS) at 1 to 3 months.       50         Analysis 2.1. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       50         Outcome 2 Cosmesis (WES, Other) at 1 to 3 months.       51 <tr< td=""><td></td><td>41</td></tr<>		41
Analysis 1.26. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 26 Cosmesis (CVAS) at 1 to 3       42         Analysis 1.27. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 27 Cosmesis (CVS) at 9 to 12       43         Analysis 1.28. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 28 Cosmesis (WES, Other) at 5       44         Analysis 1.28. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at 1       45         Analysis 1.29. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 1       45         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 9       46         Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (min).       48         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (MIN).       48         Analysis 1.32. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (octyleyanoacrylate - Dermabond),       50         Outcome 1 Cosmesis (CVAS) at 1 to 3 months.       50         Analysis 2.3. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (octyleyanoacrylate - Dermabond),       50         Outcome 2 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA		42
months by tissue adhesive.42Analysis 1.27. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 27 Cosmesis (CVS) at 9 to 1243Analysis 1.28. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 28 Cosmesis (WES, Other) at 144Analysis 1.29. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at 144Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at 946Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 946Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).47Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).48Analysis 1.33. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Ease of Procedure (VAS).48Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Complete (min).49Analysis 2.1. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (ocrylcyanoacrylate - Dermabond), Outcome 1 Cosmesis (WES, Other) at 5 to 14 days.50Analysis 2.3. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (ocrylcyanoacrylate - Dermabond), Outcome 4 Cosmesion 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (ocrylcyanoacrylate - Dermabond), Outcome 4 Complete (min).51Analysis 2.4. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (ocrylcyanoacrylate - Dermabond), Outcome 4 Complete (min).52Analysis 2.5. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (ocrylcyanoacrylate - Dermabond), 		44
Analysis 1.27. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 27 Cosmesis (CVS) at 9 to 12       43         Manalysis 1.28. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 28 Cosmesis (WES, Other) at 1       44         Analysis 1.29. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at 1       44         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 9       46         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 9       47         Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Time to Complete (min).       48         Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (min).       48         Analysis 2.1. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (ocryleyanoacrylate - Dermabond),       50         Outcome 1 Cosmesis (CVAS) at 1 to 3 months.       51         Analysis 2.3. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (ocryleyanoacrylate - Dermabond),       51         Outcome 2 Cosmesis (WES, Other) at 5 to 14 days.       51         Analysis 2.3. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (ocryleyanoacrylate - Dermabond),       52         Outcome 4 Pain (VAS).		42
months by tisue adhesive.       43         Analysis 1.28. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 28 Cosmesis (WES, Other) at 5       44         Analysis 1.29. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at 9       45         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at 9       46         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.33. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Ease of Procedure (VAS).       48         Analysis 1.33. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 1 Cosmesis (WES, Other) at 1 to 3 months.       50         Analysis 2.3. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.5. Comparison 2 BCA		74
Analysis 1.28. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 28 Cosmesis (WES, Other) at 5       4         Analysis 1.29. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at 1       6         to 3 months by tissue adhesive.       4         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 9       5         to 12 months by tissue adhesive.       46         Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 9       6         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       46         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (min).       48         Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (WAS).       49         Analysis 1.34. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       0         Outcome 1 Cosmesis (WAS) other) at 1 to 3 months.       51         Analysis 2.3. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       0         Outcome 2 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       0         Outcome 4 Pain (VAS).		43
to14 days by rissue adhesive.44Analysis 1.29. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at 145to3 months by rissue adhesive.45Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 946to12 months by rissue adhesive.46Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).47Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (min).48Analysis 1.33. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Ease of Procedure (VAS).49Analysis 1.34. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (octyleyanoacrylate - Dermabond), Outcome 1 Cosmesis (CVAS) at 1 to 3 months.50Analysis 2.2. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (octyleyanoacrylate - Dermabond), Outcome 2 Cosmesis (WES, Other) at 1 to 3 months.51Analysis 2.3. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (octyleyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.51Analysis 2.4. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (octyleyanoacrylate - Dermabond), Outcome 4 Pain (VAS).52Analysis 2.5. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (octyleyanoacrylate - Dermabond), Outcome 4 Pain (VAS).51Analysis 2.6. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (octyleyanoacrylate - Dermabond), Outcome 6 Complete (min).53Analysis 2.6. Comparison 3 Regular OCA (octyleyanoacrylate - Histoacryl) v		45
Analysis 1.29. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at 1       45         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 9       46         Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.33. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Ease of Procedure (VAS).       48         Analysis 1.33. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 33 Ease of Procedure (VAS).       48         Analysis 1.34. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (octyleyanoacrylate - Dermabond),       50         Outcome 1 Cosmesis (CVAS) at 1 to 3 months.       50         Analysis 2.3. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (octyleyanoacrylate - Dermabond),       51         Outcome 2 Cosmesis (WES, Other) at 5 to 14 days.       51         Analysis 2.3. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (octyleyanoacrylate - Dermabond),       51         Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       52         Analysis 2.3. Comparison 2 BCA (butyleyanoacrylate - Histoacryl) versus OCA (octyleyanoacrylate - Dermabond),       51         Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       52         Analysis		44
to 3 months by tissue adhesive.       45         Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 9       46         Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (min).       48         Analysis 1.33. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (MAS).       48         Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Complications.       49         Analysis 2.1. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Complications.       49         Analysis 2.1. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       0         Outcome 1 Cosmesis (CVAS) at 1 to 3 months.       50         Analysis 2.3. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       0         Outcome 2 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       52         Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       52         Outcome 4 Pain (VAS).       53 </td <td></td> <td></td>		
Analysis 1.30. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 9       46         Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (min).       48         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (MAS).       46         Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Ease of Procedure (VAS).       48         Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Complications.       49         Analysis 2.1. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       0         Outcome 1 Cosmesis (CVAS) at 1 to 3 months.       50         Analysis 2.3. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       0         Outcome 2 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       51         Outcome 4 Pain (VAS).       52       53         Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       51         Outcome 4 Pain (VAS).       53       53         Analysis 2.6. Comparison 2 BCA (		45
to 12 months by tissue adhesive.446Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).477Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (min).48Analysis 1.33. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 33 Ease of Procedure (VAS).49Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Complications.49Analysis 1.34. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 1 Cosmesis (CVAS) at 1 to 3 months.50Analysis 2.2. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 2 Cosmesis (WES, Other) at 5 to 14 days.51Analysis 2.3. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.51Analysis 2.4. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 4 Pain (VAS).52Analysis 2.5. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).53Analysis 2.6. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).53Analysis 2.6. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).53Analysis 2.6. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).53<		
Analysis 1.31. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).       47         Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (min).       48         Analysis 1.33. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 33 Ease of Procedure (VAS).       48         Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Complications.       49         Analysis 2.1. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       50         Outcome 1 Cosmesis (CVAS) at 1 to 3 months.       50         Analysis 2.3. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       51         Outcome 2 Cosmesis (WES, Other) at 5 to 14 days.       51         Analysis 2.3. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       51         Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       52         Outcome 4 Pain (VAS).       52         Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       53         Outcome 5 Time to Complete (min).       53         Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),		46
Analysis 1.32. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (min).       48         Analysis 1.33. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 33 Ease of Procedure (VAS).       48         Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Complications.       49         Analysis 1.34. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       50         Outcome 1 Cosmesis (CVAS) at 1 to 3 months.       50         Analysis 2.3. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       51         Analysis 2.3. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       51         Outcome 2 Cosmesis (WES, Other) at 5 to 14 days.       51         Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       52         Outcome 4 Pain (VAS).       52         Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       53         Outcome 5 Time to Complete (min).       53         Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       53         Outcome 5 Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       53         Outcome 6 Complications.       53		
Analysis 1.33. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 33 Ease of Procedure (VAS).       48         Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Complications.       49         Analysis 2.1. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 1 Cosmesis (CVAS) at 1 to 3 months.       50         Analysis 2.2. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 2 Cosmesis (WES, Other) at 5 to 14 days.       51         Analysis 2.3. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 4 Pain (VAS).       51         Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).       53         Analysis 3.1. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond), Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond), Outcome 1 Complications.       54		48
Analysis 1.34. Comparison 1 Tissue Adhesive versus Standard Wound Closure, Outcome 34 Complications.       49         Analysis 2.1. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 1 Cosmesis (CVAS) at 1 to 3 months.       50         Analysis 2.2. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 2 Cosmesis (WES, Other) at 5 to 14 days.       51         Analysis 2.3. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 4 Pain (VAS).       52         Analysis 2.5. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).       53         Analysis 2.6. Comparison 2 BCA (burylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond), Outcome 1 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.       54         APPENDICES       55         WHAT'S NEW       56<		48
Outcome 1 Cosmesis (CVAS) at 1 to 3 months.50Analysis 2.2. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 2 Cosmesis (WES, Other) at 5 to 14 days.51Analysis 2.3. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.51Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 4 Pain (VAS).51Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).52Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 6 Complete (min).53Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Histoacryl) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.54APPENDICES55WHAT'S NEW56HISTORY56CONTRIBUTIONS OF AUTHORS57DECLARATIONS OF INTEREST57SOURCES OF SUPPORT57		49
Analysis 2.2. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 2 Cosmesis (WES, Other) at 5 to 14 days.       51         Analysis 2.3. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 4 Pain (VAS).       52         Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).       53         Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.       54         APPENDICES       55         WHAT'S NEW       56         HISTORY       56         ONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57		
Outcome 2 Cosmesis (WES, Other) at 5 to 14 days.       51         Analysis 2.3. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 4 Pain (VAS).       52         Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).       53         Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.       54         APPENDICES       55         WHAT'S NEW       56         HISTORY       56         ONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57	Outcome 1 Cosmesis (CVAS) at 1 to 3 months.	50
Analysis 2.3. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 4 Pain (VAS).       52         Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).       53         Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.       54         APPENDICES       54         HISTORY       56         CONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57		
Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.       51         Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 4 Pain (VAS).       52         Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).       53         Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.       54         APPENDICES       54         HISTORY       56         HISTORY       56         ONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57		51
Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 4 Pain (VAS).       52         Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).       53         Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.       54         APPENDICES       55         WHAT'S NEW       56         HISTORY       56         CONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57		
Outcome 4 Pain (VAS).       52         Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).       53         Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.       54         APPENDICES       55         WHAT'S NEW       56         HISTORY       56         CONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57		51
Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       53         Outcome 5 Time to Complete (min).       53         Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       53         Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.       54         APPENDICES       55         WHAT'S NEW       56         HISTORY       56         ODECLARATIONS OF AUTHORS       57         SOURCES OF SUPPORT       57		
Outcome 5 Time to Complete (min).       53         Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.       54         APPENDICES       55         WHAT'S NEW       56         HISTORY       56         CONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57	Outcome 4 Pain (VAS).	52
Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond),       53         Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.       54         APPENDICES       55         WHAT'S NEW       56         HISTORY       56         CONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57		
Outcome 6 Complications.       53         Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.       54         APPENDICES       55         WHAT'S NEW       56         HISTORY       56         CONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57		53
Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome 1 Complications.       54         APPENDICES       55         WHAT'S NEW       56         HISTORY       56         CONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57		
- Dermabond HV), Outcome 1 Complications.       54         APPENDICES       55         WHAT'S NEW       56         HISTORY       56         CONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57		53
APPENDICES       55         WHAT'S NEW       56         HISTORY       56         CONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57		_ ,
WHAT'S NEW       56         HISTORY       56         CONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57	•	-
HISTORY       56         CONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57		
CONTRIBUTIONS OF AUTHORS       57         DECLARATIONS OF INTEREST       57         SOURCES OF SUPPORT       57		
DECLARATIONS OF INTEREST    57      SOURCES OF SUPPORT    57		-
SOURCES OF SUPPORT         57		
	INDEX TERMS	58

## [Intervention Review]

# Tissue adhesives for traumatic lacerations in children and adults

Ken J Farion<sup>1</sup>, Kelly F Russell<sup>2</sup>, Martin H Osmond<sup>3</sup>, Lisa Hartling<sup>4</sup>, Terry P Klassen<sup>5</sup>, Tamara Durec<sup>6</sup>, Ben Vandermeer<sup>7</sup>

<sup>1</sup>Departments of Pediatrics and Emergency Medicine, University of Ottawa, Ottawa, Canada. <sup>2</sup>Department of Paediatrics, Alberta Children's Hospital, Calgary, Canada. <sup>3</sup>Department of Pediatrics, University of Ottawa, Ottawa, Canada. <sup>4</sup>University of Alberta, Evidence-based Practice Centre, Edmonton, Canada. <sup>5</sup>Department of Pediatrics, University of Alberta, Edmonton, Canada. <sup>6</sup>Aberhart Centre One, Room 9418, Evidence-based Practice Centre, Edmonton, Canada. <sup>7</sup>Department of Pediatrics, Alberta Research Centre for Child Health Evidence & University of Alberta Evidence-based Practice Centre, Edmonton, Canada

Contact address: Ken J Farion, Departments of Pediatrics and Emergency Medicine, University of Ottawa, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario, K1H 8L1, Canada. farion@cheo.on.ca.

Editorial group: Cochrane Wounds Group.

**Publication status and date:** Edited (no change to conclusions), published in Issue 1, 2009. **Review content assessed as up-to-date:** 30 September 2007.

Citation: Farion KJ, Russell KF, Osmond MH, Hartling L, Klassen TP, Durec T, Vandermeer B. Tissue adhesives for traumatic lacerations in children and adults. *Cochrane Database of Systematic Reviews* 2002, Issue 3. Art. No.: CD003326. DOI: 10.1002/14651858.CD003326.

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# ABSTRACT

#### Background

Tissue adhesives have been used for many years to close simple lacerations as an alternative to standard wound closure (sutures, staples, adhesive strips). Potential advantages over standard wound closure include ease of use, decrease in pain, time to apply and not requiring a follow-up visit for removal. Whilst studies have compared tissue adhesives with standard wound closure to determine the cosmetic outcome and other secondary outcomes no systematic review was previously available, so that no generalizable, definitive answers about the effectiveness of tissue adhesives existed.

#### Objectives

To summarize the best available evidence for the effects of tissue adhesives on the healing of traumatic lacerations in children and adults.

#### Search methods

We searched the Cochrane Wounds Group Specialised Trials Register (October 2007), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 3, 2007), MEDLINE (1950 to October Week 1 2007), EMBASE (1980 to 2007 Week 41), CINAHL (1982 to October Week 2 2007), Web of Science - Science Citation Index (1975 to April 29, 2007), seven clinical trial registries, and reference lists of articles. We also contacted manufacturers and researchers in the field.

#### Selection criteria

Randomised controlled trials comparing tissue adhesives with standard wound closure or one tissue adhesive compared with another tissue adhesive for acute, linear, low tension, traumatic lacerations in an emergency or primary care setting.

#### Data collection and analysis

Two authors independently assessed trial quality and extracted data. Study authors were contacted for additional information. Information on adverse effects was collected from the trials. Outcomes of cosmesis (subgroups of age, wound location and need for deep sutures), pain, procedure time, ease of use, and complications were analysed separately for two comparisons: 1) tissue adhesive compared with standard wound closure; and 2) tissue adhesive compared with another tissue adhesive.

#### Main results

Thirteen studies were included in this review. Eleven studies compared a tissue adhesive with standard wound closure. No significant difference was found for cosmesis at any time point examined, using either Cosmetic Visual Analogue Scale (CVAS) or Wound Evaluation Score (WES). Pain scores (Parent VAS weighted mean difference (WMD) -13.4 mm; 95% CI -20.0 to -6.9) and procedure time (WMD -4.7 minutes; 95% CI -7.2 to -2.1) significantly favoured tissue adhesives. Only one study reported on ease of use, favouring standard wound closure. Small but statistically significant risk differences were found for dehiscence (favouring standard wound care, Number Needed to Harm (NNH) 40; 95% CI 20 to 1168) and erythema (favouring tissue adhesive, NNH 10; 95% CI 5 to 239). Other complications were not significantly different between treatment groups.

Two studies compared tissue adhesives. One study compared two different tissue adhesives, butylcyanoacrylate with octylcyanoacrylate, for pediatric facial lacerations and found no significant difference for cosmesis, pain, procedure time, or complications. Another study compared two different formulations (viscosities) of octylcyanoacrylate to assess the incidence of product migration as a proxy for complications of application; the high-viscosity product migrated on significantly fewer participants.

#### Authors' conclusions

Tissue adhesives are an acceptable alternative to standard wound closure for repairing simple traumatic lacerations. They offer the benefit of decreased procedure time and less pain, when compared to standard wound closure. A small but statistically significant increased rate of dehiscence with tissue adhesives is observed.

#### PLAIN LANGUAGE SUMMARY

#### Tissue adhesives for traumatic lacerations in children and adults

Cuts (lacerations) often need to be closed to ensure proper healing, and prevent infection or unattractive scarring. Wounds may be closed with stitches (sutures), staples, tapes or glue (tissue adhesive). The review found that glue is an excellent substitute for stitches, staples or tapes to close simple cuts. Glue causes less pain, is quicker and needs no follow up for removal. A slightly higher number of cuts may break open (dehisce) after being glued, compared to cuts closed with stitches, staples or tapes. Though there are a few different types of glue available, no one glue seems to be superior.

# BACKGROUND

Traumatic wounds, including lacerations, are one of the most common reasons for people presenting to the Emergency Department (ED) (Sibert 1981). The management of these lacerations involves cleaning the wound and then re-approximating the wound edges until natural healing occurs. Without proper closure, the patient is at increased risk of infection and excessive scar formation, which results in a poor cosmetic outcome (Hollander 1999).

Traditionally, approximation of these lacerations has been accomplished using sutures, which either dissolve after a number of days, or require another visit for removal. Insertion of sutures requires a local anaesthetic agent to reduce the pain associated with the procedure. Infiltration of the wound with a local anaesthetic can be quite painful. Small children with lacerations pose further challenges, as they may require sedation to reduce pain, emotional distress and movement during the procedure. This adds time and complexity to the patient's ED visit (Osmond 1999a; Osmond 2000). Other standard wound closure (SWC) options include staples and adhesive strips.

For many years, tissue adhesive compounds (glue) made from cyanoacrylates have been available to close simple lacerations. These compounds are supplied as liquid monomers that quickly form a strong bond over the approximated wound. This keeps the edges together until healing has occurred. Practitioners experienced in suturing find them quick and easy to use following a brief orientation to the product and its limitations. They are relatively painless for the patient and provide an excellent cosmetic outcome (Osmond 1999a; Osmond 2000; Sells 1999). No follow-up appointment for suture removal is required and one study has shown them to be a cost-effective alternative to sutures (Osmond 1995).

There is an increasing amount of literature supporting the use of

tissue adhesives for various minor lacerations (Applebaum 1993; Barnett 1998; Bruns 1998; Elmasalme 1995; Goktas 2002; Holger 2004; Mattick 2002a; Mizrahi 1988; Morton 1988; Osmond 1999a; Perron 2000; Quinn 1993; Quinn 1998a; Saxena 1999; Schultz 1979; Simon 1997; Singer 1998; Singer 2003; Watson 1989; Zempsky 2001). Initially, the evidence was in the form of successful case series that lacked controls or blinded outcome assessments. A number of randomised controlled trials have since been reported which advocate tissue adhesives in their respective study populations. However, the evidence has not been summarised and interpreted in a systematic and rigorous review.

# OBJECTIVES

The objective of this review was to summarize the best available evidence for the effects of tissue adhesives on the healing of traumatic lacerations in children and adults.

# Specific Aims

To compare the relative effectiveness of:

1. tissue adhesives compared with standard wound closure (i.e., sutures, staples or adhesive strips); and

2. comparison of different tissue adhesives for repair of lacerations in subgroups of patients of differing age (pediatric versus adult), location of the laceration (face versus body) and type of laceration (requiring versus not requiring deep sutures).

# METHODS

#### Criteria for considering studies for this review

#### **Types of studies**

We included randomised controlled trials (RCTs) comparing tissue adhesives with standard wound closure (i.e., sutures, staples, adhesive strips) or one tissue adhesive compared with another tissue adhesive.

## **Types of participants**

We considered studies that recruited people of any age in an ED, outpatient clinic, walk-in clinic or other primary care setting. The wounds had to be acute, linear lacerations, less than 12 hours old, resulting from blunt or sharp trauma, excluding stellate lacerations, puncture wounds, and mammalian bites. Wounds of any length, width and depth were included, provided that the edges could be approximated with minimal tension after deep sutures were placed, if required. Also excluded were studies of wounds which were infected, heavily contaminated or devitalized, those crossing joints or mucocutaneous junctions, those in hair-bearing areas, and those in people with keloid formation or chronic illness which could impair healing (e.g., peripheral vascular disease, diabetes). We did not consider any trials that evaluated tissue adhesives in the operating room for closure of surgical incisions (see Coulthard 2004 for data on surgical incisions), or trials dealing with other types of wounds (e.g., ulcers, skin grafts, dental repair).

#### **Types of interventions**

We considered studies in which participants were randomised to closure of their laceration by one of two or more methods, one of which was a tissue adhesive. The comparison arms were either another form of skin closure (i.e., sutures, staples, adhesive strips) or a second tissue adhesive.

#### Types of outcome measures

#### **Primary outcomes**

We considered all patient outcomes reported by the included studies. The primary measure was cosmetic outcome, as determined by one or more blinded evaluators, using one or more validated cosmetic scores, such as the Cosmetic Visual Analogue Scale or Wound Evaluation Score.

#### Secondary outcomes

Other outcomes that we included when available were: patient pain during the procedure; time needed to complete the procedure; the ease of the procedure; and the occurrence of any complications (e.g., infection, wound dehiscence, erythema, or tissue adhesive migration).

#### Search methods for identification of studies

#### **Electronic searches**

For this update we searched the databases: Cochrane Wounds Group Specialised Register (October 2007); The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 3, 2007); Ovid MEDLINE (1950 to October Week 1 2007); Ovid EMBASE (1980 to 2007 Week 41); Ovid CINAHL (1982 to October Week 2 2007); Web of Science - Science Citation Index (1975 to April 29, 2007)

The following search strategy was used in The Cochrane Central Register of Controlled Trials (Online Version):

#1 MeSH descriptor Lacerations explode all trees

Copyright  $\textcircled{\sc 0}$  2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Tissue adhesives for traumatic lacerations in children and adults (Review)

#2 lacerat\*
#3 traumatic NEXT (wound\* or injur\*)
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Tissue Adhesives explode all trees
#6 MeSH descriptor Acrylates explode all trees
#7 tissue NEXT adhesive\*
#8 acrylate\* or bucrylate\* or cyanoacrylate\* or enbucrilate\*
#9 glu or glue or glues
#10 (#5 OR #6 OR #7 OR #8 OR #9)
#11 (#4 AND #10)

For the Ovid MEDLINE search strategy see Appendix 1; for Ovid EMBASE see Appendix 2; for Ovid CINAHL see Appendix 3 and for Web of Science see Appendix 4. Ovid MEDLINE was searched using the following strategy in combination with the Cochrane highly sensitive search strategy for identifying reports of randomised controlled trials (Higgins 2005). The Ovid EMBASE and CINAHL searches were combined with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN). We did not restrict the search by language or publication status. The following clinical trials registers were searched in June 2007:

- ClinicalTrials.gov (US).
- CenterWatch Clinical Trials Listing Service (US).
- Current Controlled Trials (International).
- National Research Register (UK).
- Trials Central (International).

• WHO International Clinical Trials Registry Platform (International).

• CRISP (Computer Retrieval of Information on Scientific Projects) Database (US)

#### Searching other resources

Citation list searches of all selected articles were undertaken. In addition we contacted the primary author of all selected articles and the manufacturers of tissue adhesive products (B. Braun Melsungen AG, Closure Medical Corp, GluStitch Inc, Loctite Inc, Sherwood-Davis & Geck).

#### Data collection and analysis

#### Selection of studies

Two authors independently examined the title and abstracts of trials generated by the search to identify potentially relevant trials (KF, KR). With the full text of these articles, two authors independently assessed each study for inclusion using a standardized form with eligibility criteria (KF, KR). We resolved disagreements by consensus or by a third author when necessary.

#### Data extraction and management

One author (KF) extracted data and a second author (KR) checked for accuracy. We used a standard data form to capture the following information:

• characteristics of the study (design, method of

randomisation, withdrawals/dropouts, funding source);study participants (age, wound location, wound

characteristics);

• intervention (type of tissue adhesive, wound preparation, wound dressing);

- comparison intervention (suture or other tissue adhesive);
- outcome measures (type of scoring, timing of assessment,
- complications); and
  - results.

If two unique publications reported data on the same study, we extracted all data. If discrepancies were detected, clarification was sought from the author, or we included the more conservative results. We requested additional unpublished data from primary authors and included if available.

#### Assessment of risk of bias in included studies

Two authors independently assessed the quality of each selected study for quality using two established methods. First, each study was evaluated using the previously validated Jadad 5-point scale to assess randomisation, blinding, and withdrawals/dropouts (Jadad 1996). Next, concealment of allocation was assessed as adequate, inadequate or unclear using the methodology described by Schulz 1995. Any discrepancies were resolved through discussion.

#### Data synthesis

Medians were substituted for means where means were not reported (Bruns 1998; Mattick 2002a; Osmond 1999a; Simon 1997). Where there were two observers rating cosmetic wound appearances (CVAS), their summary measures were pooled (Bruns 1998; Holger 2004; Simon 1997; Zempsky 2001). Where standard deviations or any variations thereof (e.g., standard error, variance) were not reported, P values from t-tests were inverted to obtain standard deviations (Quinn 1993; Quinn 1998a). If not stated, p-values were assumed to be two-sided. Upper bound pvalues were also inverted giving a conservative estimate in some cases (Quinn 1993; Quinn 1998a). Non-parametric confidence intervals (CI) were used to obtain standard deviations where not reported (Bruns 1998). Therein a robustness to the 'normality' assumption was assumed. In cases where only p-values from nonparametric tests were reported, an average of the standard deviations from other trials with that particular outcome was substituted (Mattick 2002a; Simon 1997).

Two comparisons were established a priori for separate analyses: (1) tissue adhesive compared with standard wound closure (SWC); and (2) tissue adhesive compared with tissue adhesive. Continuous

Tissue adhesives for traumatic lacerations in children and adults (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

data (i.e., CVAS, pain scores, time to complete, ease of the procedure) were converted to a mean difference and an overall weighted mean difference (WMD) with 95% confidence intervals (95% CI) was calculated. The Wound Evaluation Score (WES) was reported as a dichotomous outcome in each study (i.e., optimal or suboptimal cosmesis), and thus we expressed it as a relative risk (RR) and a pooled relative risk with 95% CI. Complications (i.e., dehiscence, infection, erythema, delayed closure, discharge, tissue adhesive migration) were presented as risk differences (RD); since some studies had zero events in both treatment groups a relative risk could not be calculated. The number needed to harm (NNH) was also calculated for further clarification where the results were significant. The baseline SWC risks were combined using the same weights used in the corresponding meta-analysis.

Almost all pain VAS and time to complete the procedure data were skewed with a right tail (Altman 1996), however, almost all treatment groups were sufficiently large to meet the requirements of the central limit theorem. Thus, the distribution of the means, not the singular data points, were approximately normal and we could use the WMD to summarize this data.

Results for tissue adhesives compared with standard wound closure were calculated using random effects models (DerSimonian 1986), since two tissue adhesives were used (e.g., butylcyanoacrylate (Histoacryl TM), octylcyanoacrylate (Dermabond TM)) and treatments varied for standard wound closures (e.g., suturing, staples, adhesive strips). Statistical heterogeneity was quantified using the I<sup>2</sup> statistic (Higgins 2003). The I<sup>2</sup> statistic indicates the per cent variability due to between study variability as opposed to within study variability. An I<sup>2</sup> greater than 50% may be considered large. Possible sources of heterogeneity were explored by subgroup and sensitivity analyses using the primary outcomes at the most popular time point (i.e., CVAS at one to three months and WES at one to three months). Subgroup analyses examined the effect of different age groups (pediatric, less than 18 years versus adult, greater than or equal to 18 years), wound location (face versus body), type of tissue adhesive, and methodological quality criteria (components of the Jadad score, funding source) using a subgroup chi squared test (Deeks 2001). Subgroups of extent of laceration (lacerations requiring deep sutures versus not) and allocation concealment could not be analysed due to insufficient data. Sensitivity analyses assessed for the choice of statistical model (i.e., fixed-effect versus random-effects model).

Results for the tissue adhesive compared with another tissue adhesive comparisons were calculated using fixed-effect models, since there was only one study included for each unique pair of tissue adhesives compared.

Publication bias was tested visually using the funnel plot and quantitatively using weighted regression (Egger 1997).

# RESULTS

#### **Description of studies**

See: Characteristics of included studies; Characteristics of excluded studies.

Using the various search strategies, we identified more than 850 unique articles. From these, 45 were selected as potentially relevant, including one abstract (Symeonoglou 1998) only identified through the Cochrane Wounds Group trials register, and one trial (Stuart 1999) only identified through the clinical trials registers. No additional articles were identified by citation searches, or through correspondence with authors and tissue adhesive manufacturers.

Two authors (KF and KR) assessed the abstracts, and full text when available, of the 45 potential articles for relevance using a standard inclusion/exclusion form. Unanimous agreement was attained on all relevance decisions. Fifteen unique studies were selected, represented by 25 of the 45 articles. Six of the unique studies were represented by more than one identified publication, due to the presence of abstracts, separate reporting of early and late cosmetic outcomes, or analysis of the results sub grouped by other variables. One study (Zempsky 2001) was initially represented by the interim results published in abstract format only; the completed results have now been published and these data have been updated. Three studies, despite meeting inclusion for relevance, have been subsequently excluded. The first study (Singer 2002), a multicentre trial that included both traumatic lacerations and operative wounds, reported combined results for both populations. Four of the 10 sites within the multi-centre trial dealt with lacerations. Two of these sites have independently reported their results and are included in our review (Bruns 1998; Singer 1998). Multiple attempts to obtain the unpublished data from the remaining two sites have been unsuccessful. The second excluded study (Symeonoglou 1998) was an abstract of a RCT evaluating sutures and two tissue adhesives for closure of facial lacerations. No results were presented in the abstract, no subsequent publication of results has been found, and multiple attempts to contact the authors have been unsuccessful. The last study (Stuart 1999) was identified through a clinical trials register. Attempts to contact the investigator for the status of the study have been unsuccessful and no published results have been found.

The remaining 20 excluded articles were comprised of four review articles (Brown 1997; Liebelt 1997; Mattick 2002b; Sportsmed 1997), five studies dealing with operative incisions or other wounds (Alamouti 1998; Bernard 2001; Greene 1999; Ludlow 2000; Qureshi 1997), one study dealing with high tension lacerations across joints (Saxena 1999), two studies that were not randomised (Charters 2000; Doraiswamy 2003), one observational study without a comparison arm (Giri 2004), one study that used tissue adhesives in a non-traditional method for scalp lacerations (Hock 2002), and six studies that did not include tissue adhesives (Eaglstein 2002; Farris 1981; Fatovich 1995; Giovannacci 2002; Quinn 2003; Sutton 1985).

Thirteen studies met the inclusion criteria for this review. Eleven

Tissue adhesives for traumatic lacerations in children and adults (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

studies compared a tissue adhesive with standard wound closure, five with butylcyanoacrylate (Histoacryl TM)(Barnett 1998; Goktas 2002; Quinn 1993; Schultz 1979; Simon 1997) and six with octylcyanoacrylate (Dermabond TM) (Bruns 1998; Holger 2004; Mattick 2002a; Quinn 1998a; Singer 1998; Zempsky 2001). The standard wound closure method was sutures in seven studies (Barnett 1998; Goktas 2002; Holger 2004; Quinn 1993; Quinn 1998a; Schultz 1979; Simon 1997), adhesive strips in two studies (Zempsky 2001; Mattick 2002a), and a mixture of closure methods in the remaining two studies (Bruns 1998; Singer 1998), though the majority of participants received sutures. In one of the studies comparing tissue adhesive with sutures (Holger 2004), the tissue adhesive was actually compared with two types of suture (i.e., absorbable and non-absorbable) in a three-arm trial; additional data from the author allowed us to combine these two standard wound closure arms.

Seven of the 11 studies were limited to children (Barnett 1998; Bruns 1998; Holger 2004; Mattick 2002a; Quinn 1993; Simon 1997; Zempsky 2001), two were limited to adults (Goktas 2002; Quinn 1998a), and the remaining two studies included all ages (Schultz 1979; Singer 1998). Three of the pediatric studies (Holger 2004; Quinn 1993; Zempsky 2001) and one of the studies without age restriction (Schultz 1979) were limited to facial lacerations. Four studies (Barnett 1998; Mattick 2002a; Quinn 1993; Schultz 1979) excluded deep suture lacerations. The remaining studies did not stratify their results by extent of laceration.

Two studies compared two tissue adhesives. The first study (Osmond 1999a) compared butylcyanoacrylate and octylcyanoacrylate for the closure of pediatric facial lacerations not requiring deep sutures. The other study (Singer 2003) compared high-viscosity octylcyanoacrylate and low-viscosity (standard) octylcyanoacrylate for the closure of any laceration amenable to tissue adhesive closure in children and adults.

Two studies allowed participants with more than one laceration to be enrolled; each laceration was assessed independently. The first study (Quinn 1998a) randomised each laceration independently, while the other study (Bruns 1998) randomised the participant and all lacerations were assigned to that treatment arm. This nonindependence occurred in only two participants, each with two lacerations, and would not affect the results significantly. All other studies randomised and assessed one laceration per participant. All studies were published in English, except Schultz 1979 (Danish). All studies were conducted in an ED setting.

#### **Outcome measures**

Cosmesis was the primary outcome reported by all selected studies except one (Singer 2003). Most researchers used the Cosmetic Visual Analogue Scale, the Wound Evaluation Score, or a combination of these two measures of cosmesis. The timing for cosmesis assessments varied somewhat between studies, but three distinct time periods became evident allowing grouping: (1) suture/staple removal and complication follow up at 5 to 14 days; (2) early healing at 1 to 3 months; and (3) late healing at 9 to 12 months. Early cosmesis scores (7 to 14 days) have been shown to poorly correlate with late scores (6 to 9 months) (Hollander 1995b).

The Cosmetic Visual Analogue Scale (CVAS) is a 100 mm line, with zero being "worst scar imaginable" and 100 being the "best scar imaginable". A blinded assessor, usually a plastic surgeon, rates the appearance of each laceration, either in person or from a standardized photograph, by placing a mark along the line. The CVAS was developed to assess laceration repairs in clinical trials. It has been shown to be a reliable and valid outcome measure of longterm cosmesis with excellent intra- and inter-rater agreement. A measure of 12 to 15 mm has been shown to be the minimum clinically important difference (MCID) between optimal and sub-optimal scars using the WES scoring method (Quinn 1995; Quinn 1998a). A modified version of the CVAS was used in one study with the participant rating their satisfaction with their scar (Singer 1998). Since cosmesis ultimately deals with the patient's perception of how well the laceration has healed, these results were combined with other CVAS values.

The Wound Evaluation Score (WES) assesses six clinical variables of each scar: absence of step-off, contour irregularities, wound margin separation greater than two millimetres, edge inversion, excessive distortion, and overall cosmetic appearance. Each variable is given a score of zero or one, with a total score of six considered "optimal" (Hollander 1995a). Results are reported as dichotomous data, the number of optimal scars in each group. Though determining this score requires that the evaluator be able to assess the scar in person, it offers the advantage of providing specific feedback of the imperfections that have resulted in a suboptimal scar. One study (Barnett 1998) used a non-validated five-point scale (i.e. 1 = poor, 5 = excellent) to assess cosmesis. Following communication with the author, we converted those participants with "excellent" scores to "optimal" to combine with other WES assessments. Another study (Quinn 1993) used both CVAS and a non-validated three-point categorical scale (i.e., unacceptable, acceptable, excellent) to assess cosmesis. We could not determine a justifiable way to combine the three-point scale with WES, so these data were excluded. Finally, Schultz 1979 used a non-validated rating of "acceptable" versus "unacceptable"; "acceptable" was translated to "optimal" to be combined with other categorical WES assessments.

The primary outcome in the remaining study (Singer 2003) was the incidence of migration of the tissue adhesive greater than 1 cm from the wound edges. This outcome was chosen as a proxy for complications during application (i.e., for wounds adjacent to the eyes where excessive migration could cause the eyelids to become stuck together).

We assessed secondary outcomes of pain associated with the procedure and ease of the procedure using visual analogue scales. The time to complete the procedure, when included in the results, was reported as a mean number of minutes for each study group.

The remaining secondary outcomes considered were complications: incidents of infection, dehiscence, induration or erythema, discharge, and the need for delayed closure.

#### **Risk of bias in included studies**

No studies were double-blind due to the nature of the interventions (impossible to insert "placebo" sutures or staples), thus Jadad scores ranged from one to three. Four studies scored a three (two points on randomisation and one point for reporting withdrawals) (Goktas 2002; Holger 2004; Osmond 1999a; Quinn 1998a). Three studies scored a two (one point for randomisation and one point for withdrawals) (Bruns 1998; Quinn 1993; Schultz 1979). Two studies scored two points for randomisation (Mattick 2002a; Singer 2003). The remaining four studies scored a one (randomisation) (Barnett 1998; Simon 1997; Singer 1998; Zempsky 2001). Two studies (Osmond 1999a; Singer 2003) reported adequate allocation concealment.

The 'Characteristics of Included Studies' table provides further information on the sample size, population/wound type studied, intervention, outcome measures, funding source, and assessment of the methodological quality/allocation concealment for each of the studies included in this review.

#### **Effects of interventions**

# Tissue adhesive compared with standard wound closure

#### **Cosmetic scores**

There were nine studies with 889 lacerations that compared tissue adhesives with standard wound closure using the CVAS outcome measure. Overall, there were no significant differences between tissue adhesives and standard wound closure for CVAS at any of the time points examined. Only one study measured CVAS between 5 to 14 days; the WMD showed no difference (0.0 mm; 95% CI -4.8 to 4.8; 52 lacerations (Analysis 1.1)). At 1 to 3 months, the pooled WMD was 1.6 mm (95% CI -3.2 to 6.4; seven studies with 549 lacerations (Analysis 1.2). The I<sup>2</sup> statistic was large and indicated 57% heterogeneity due to between-study heterogeneity. The CVAS pooled WMD at 9 to 12 months was 1.5 mm (95% CI -3.1 to 6.1; four studies with 237 lacerations; (Analysis 1.3)). Between-study heterogeneity was negligible (I<sup>2</sup> = 0%).

Four studies (with 364 lacerations) used the WES; there were no significant differences between treatment groups at any of the time points examined. At 5 to 14 days, the pooled RR for an optimal wound was 0.97 (95% CI 0.87 to 1.09; two studies with 195 lacerations (Analysis 1.4)). The pooled RR for an optimal wound at 1 to 3 months was 0.99 (95% CI 0.89 to 1.11; four studies with 364 lacerations; (Analysis 1.5)). The pooled RR for an optimal wound at 9 to 12 months was 1.08 (95% CI 0.89 to 1.30; two studies with 140 lacerations; (Analysis 1.6)). Between-study heterogeneity was absent at all these time points.

All subgroup analyses (i.e., age, location, need for deep sutures, tissue adhesive, Jadad score and its components, funding) except two gave insignificant findings (Analysis 01.07 through 01.30). For the subgroup by age using CVAS at 5 to 14 days, the one trial of adults found a statistically significant superiority of BCA over SWC (WMD 7.74, 95% CI 2.71 to 12.77; (Analysis 1.7)). For the subgroup by tissue adhesive using CVAS at 1 to 3 months, BCA was found to be superior to SWC (WMD 7.50, 95% CI 1.75 to 13.25; three studies with 182 lacerations; (Analysis 1.26)). The funnel plot for CVAS at one to three months did not indicate publication bias. The weighted regression bias coefficient was insignificant (P = 0.83). WES at one to three months had too few studies (N = 4) to assess publication bias.

#### Secondary outcomes

#### Pain

Six studies measured pain scores (VAS) with 570 lacerations. All VAS results were significant and favoured the tissue adhesive interventions. The pain outcome with the most studies, the parent-reported VAS, had a pooled WMD of -13.4 mm (95% CI -20.0 to -6.9; five studies with 434 lacerations; (Analysis 1.31)). Between-study heterogeneity was minimal ( $I^2$ =15%). The remaining pain outcomes contained data from only one study each. The patient-reported VAS WMD was -10.8 mm (95% CI -17.1 to -4.5). The physician-reported VAS WMD was -12.6 mm (95% CI -20.1 to -5.1). The nurse-reported VAS WMD was -14.9 (95% CI -22.5 to -7.3).

#### Time to complete the procedure

Time to complete the procedure also favoured the tissue adhesive interventions (pooled WMD -4.7 min, 95% CI -7.2 to -2.1; six studies with 584 lacerations)(Analysis 1.32). Although betweenstudy heterogeneity was large ( $I^2$ =84%), the six studies were consistent in that they all showed that tissue adhesives were much less time consuming. The large heterogeneity seems to be due to the inconsistent SDs of the various studies; the heterogeneity disappeared completely ( $I^2$ =0%) if we considered a standardized mean difference, while the result was still statistically significant.

#### Ease of procedure

Only one study (Mattick 2002a) reported ease of the procedure for the physician. These data were quite skewed; they reported a pvalue of 0.07 from a Mann-Whitney test and showed greater ease

for the SWC procedure (medians five versus nine mm)(Analysis 1.33).

#### Complications

Nine studies recorded complications on 834 lacerations. All complications were insignificant using the random-effects (RE) model, except for the incidence of dehiscence and erythema. Fewer cases of dehiscence occurred using standard wound care (Risk Difference (RD) 2.4%, 95% CI 0.1 to 4.9)(Analysis 1.34), while fewer incidences of erythema occurred when using tissue adhesives (RD -10%, 95% CI -19 to -0.4). The baseline risk of dehiscence with tissue adhesives was 3.7% and 40 (95% CI 20 to 1168) patients would need to be treated with SWC to prevent one case of dehiscence when using tissue adhesives. The baseline risk of erythema with SWC was 18.3% and 10 (95% CI 5 to 239) patients would need to be treated with tissue adhesives to prevent one incident of erythema when using SWC. Risk differences for infection, delayed closure and discharge were not significant. The baseline SWC risks were 1.1, 0, and 8.2% respectively.

#### Tissue adhesive compared with another tissue adhesive

Two studies compared tissue adhesives. No subgroup or sensitivity analyses were possible as they compared unique pairs of tissue adhesive and with different primary outcomes. As such, they are reported as unique comparisons.

#### Butylcyanoacrylate compared with octylcyanoacrylate

Osmond 1999a compared butylcyanoacrylate (Histoacryl TM) with octylcyanoacrylate (Dermabond TM) for 97 lacerations.

#### **Cosmetic scores**

There was no significant difference between butylcyanoacrylate and octylcyanoacrylate using CVAS at 1 to 3 months. The WMD was 2.5 mm (95% CI -3.6 to 8.6; 83 lacerations; (Analysis 2.1)). There was no significant difference in the WES at 5 to 14 days or at 1 to 3 months. The relative risks were 1.1 (95% CI, 0.9 to 1.3; (Analysis 2.2)) and 0.9 (95% CI, 0.7 to 1.2; (Analysis 2.3)), respectively.

#### Secondary outcomes



There was no statistically significant difference in the combined patient and parent-reported pain scores (VAS) (WMD 5.0 mm, 95% CI -14.8 to 24.7)(Analysis 2.4).

#### Time to complete the procedure

There was also no significant difference in the time required to complete the procedure (WMD 0.2 min, -1.1 to 1.5)(Analysis 2.5).

#### Ease of procedure

The study reported no significant difference for ease of procedure; however, data were incomplete and not included in the review.

#### Complications

Two complications were measured (Analysis 2.6): there was no significant difference between treatment groups in either dehiscence (RD 4%, 95% CI -3 to 11) or infection (RD 0%, 95% CI -4 to 4).

#### High-viscosity octylcyanoacrylate compared with lowviscosity octylcyanoacrylate

Singer 2003 compared high-viscosity octylcyanoacrylate (Dermabond HV TM) with low-viscosity (standard) octylcyanoacrylate (Dermabond TM)(Analysis 3.1). No efficacy estimates were available as the main outcome related to the complication of tissue adhesive migration.

The study reported a significantly higher incidence of migration with the low-viscosity product (RD 55%, 95% CI 37 to 73). There were no significant differences in the incidence of dehiscence (RD -3%, -10 to 4) or infection (RD 0%, -5 to 5)(Analysis 3.1).

### DISCUSSION

This systematic review has shown that tissue adhesives are an acceptable alternative to standard wound closure (SWC) for repairing simple traumatic lacerations.

No significant difference was found in the short or long-term cosmetic outcome between lacerations closed with tissue adhesives and SWC. Indeed, the range of plausible values (the 95% CI) are all smaller than the range of minimum clinically important differences (12 to 15 mm) suggested (Goodman 1994). No further studies simply comparing a tissue adhesive to SWCs for cosmetic outcome are necessary. No subgroup differences were found when

Tissue adhesives for traumatic lacerations in children and adults (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

participants were grouped for age or for location. No comparisons could be made within the included studies for the extent of lacerations.

While cosmesis is an important outcome for both patients and providers, other outcome measures must be considered before declaring tissue adhesives an appropriate alternative to sutures and other SWC methods. The application of tissue adhesives is significantly faster (average 4.7 minutes less) and less painful than SWC. In clinical practice, this is particularly important to consider when treating young children. Suturing wounds in this age group can be emotionally traumatic for the child (unless sedation is used) as well as the parent. Though sedation is safe and uncomplicated for the majority of patients, this adds time and increases cost and complexity.

No individual study has been able to show a significant difference in complication rates between tissue adhesives and SWC. This is due to insufficient power to detect rare outcomes, such as infection and dehiscence. However, when pooling the results of the nine studies comparing tissue adhesives to SWC, significant random-effects differences were found for erythema (favouring tissue adhesive) and dehiscence (favouring SWC). No differences were found for infection, delayed closure or discharge. This may still be due to insufficient pooled numbers of participants, calling for further clinical trials that are designed to assess complication rates rather than cosmesis, and thus are sufficiently powered to detect these rare events.

A small, but significant increased risk of dehiscence was found with tissue adhesives. The estimate of this risk difference is 2.4% (95% CI 0.1 to 4.9; Number Needed to Harm (NNH) 40, 95% CI 20 to 1168). The clinical significance of this result is difficult to interpret without further research to identify whether wound characteristics, patient characteristics, practitioner skill level/training, or different tissue adhesives influence this result. Also, it is not known whether dehisced wounds, including those that require secondary closure, have a different cosmetic outcome than those without dehiscence. Until these questions are answered, this complication should be discussed with the patient (and parent) as a potential, although infrequent, complication that would require a repeat visit for a second closure. Research to identify patients' tolerance for this potential second visit may also influence how practitioners approach this issue.

Erythema was found more often in participants treated with standard wound closure. The random-effects estimate of this risk difference is -10% (95% CI -19 to -0.4; NNH 10, 95% CI 5 to 239). It is difficult to determine the clinical significance of this finding without further data to correlate this early complication with long-term cosmesis.

While there are theoretical differences between the two tissue adhesive products currently available (butylcyanoacrylate (BCA), octylcyanoacrylate (OCA)), only one study with available data was identified that compared them directly. No significant difference was found between the two tissue adhesives for the outcomes of cosmesis, procedure time, pain, infection, or dehiscence. One other study was identified, but no data were available to include it in the review at this time. In an indirect (between study) comparison using a chi squared test (Deeks 2001), we found a significant difference that favoured BCA (WMD 7.5 versus -2.1 mm, p= 0.003) on CVAS at one to three months. Direct evidence (Oxman 1992), obtained through further tissue adhesive versus tissue adhesive trials, is required to make a definitive conclusion.

The lack of other studies comparing the two products may be due to a number of possible factors. In the United States, only octylcyanoacrylate (Dermabond TM) is available under FDA sanction. Without FDA approval of the research protocol, other tissue adhesives cannot be studied. In other countries where both products are available, there is a significant per-patient cost savings of Histoacryl TM, when used as a multi-dose vial, over Dermabond TM (Quinn 1998b). This cost difference may deter researchers from further comparisons between the products, when each has shown to be an equally acceptable alternative to standard wound care.

The final study compared a newer formulation of octylcyanoacrylate (high-viscosity) with the standard formulation to assess the incidence of migration away from the wound. The authors chose this outcome as a proxy for complications during use, where the patient's eye may become inadvertently stuck shut by adhesive migrating from a nearby wound. While this complication does rarely occur and may be theoretically prevented using a higher-viscosity tissue adhesive, migration can easily be prevented with appropriate patient selection, preparation and positioning (Farion 2003).

Two outcomes showed significant heterogeneity in the results of the included studies. The first, tissue adhesive versus SWC using CVAS at one to three months, is the outcome with the largest number of included studies. Each study relied on its own raters (plastic surgeons) to make cosmetic assessments using CVAS, which does not include a reference point of "adequate" or any other qualifier. Thus, each rater is able to set their own reference point, leading to heterogeneity in the results among studies. The other outcome, time to complete the procedure, may be explained by the various SWC methods used in the comparison arms. For example, two trials used adhesive strips, which take very little time to apply compared to trials in which sutures were used. As well, few studies clearly reported how the time was measured (start and end points), making it impossible to know if the various studies were assessing the same time period.

Two economic analyses of tissue adhesives have been published. The first analysis (Osmond 1995) compared the personnel time, supply costs and parental costs between non-absorbable percutaneous sutures, absorbable percutaneous sutures and multi-use Histoacryl TM in a Canadian ED setting, using 1993 costs. The ED overhead costs and costs associated with complications were not

included, as they were thought to be equal across all three groups, with the assumption that cosmesis was equivalent. Absorbable sutures were found to be 2.4 times more costly than tissue adhesives, while non-absorbable sutures were 6.8 times more costly, due to the need for a repeat visit. The other analysis (Zempsky 2005) compared three closure methods (adhesive strips, sutures and tissue adhesives) for simple wounds closed without complication, with subsequent dehiscence, or with subsequent infection. The authors used the literature to estimate the costs of the products used (primary closure +/- secondary closure if dehiscence occurred) and the physician's time (minutes to repair the wound multiplied by mean physician's labour rate/minute). This US-based analysis only considered octylcyanoacrylate (Dermabond TM) and did not account for costs associated with removal of non-absorbable sutures. In the end, they concluded that adhesive strips had the lowest cost per laceration overall, the lowest cost per laceration with subsequent dehiscence, and the lowest cost per laceration with subsequent infection. Tissue adhesives were found to be the most expensive alternative in all three scenarios.

An updated cost analysis is needed to compare tissue adhesives, considering these scenarios as well as the cost of procedural sedation, which is being utilized more often for lacerations repaired with sutures.

The evidence is limited by the overall low methodological quality of the included studies, as assessed by the Jadad score. Due to the types of treatments being compared, it was impossible to blind the participant or the physician, though blinded individuals did the later cosmetic assessments. Most studies failed to adequately describe the randomisation process and half did not fully report the management of dropouts or withdrawals. Similarly, only two studies adequately described their allocation concealment practices. The primary outcome of most studies is also a potential limitation, given the subjective nature of cosmesis scoring. Three studies assessed cosmesis with non-validated scoring systems.

Several factors may have affected our results. Our use of imputed values and combining parametric and non-parametric statistics may have lead to less precise results. Subgroup analyses were a necessary part of our review; unfortunately, these are indirect comparisons and are also underpowered due to lack of data. Finally, further data are required to determine whether variables such as the training level of the treating physician influence the results.

# AUTHORS' CONCLUSIONS

#### Implications for practice

• Tissue adhesives are an acceptable alternative to standard wound closure for repairing simple traumatic lacerations.

 $\cdot$  Tissue adhesives offer the benefit of rapid application and less pain. This has greatest implication for children with lacerations.

· A small but significant increased rate of dehiscence with tissue adhesives must be considered when choosing the closure method (Number Needed to Harm 40).

#### Implications for research

• Research is needed to determine the characteristics (patient, wound, product, operator) that result in an increased rate of dehiscence with tissue adhesives and whether dehiscence results in poor cosmetic outcome. This will require a very large RCT powered to detect these possible differences leading to rare events.

· Additional research is needed to compare different tissue adhesives and the relative costs of tissue adhesives versus other forms of wound closure.

• Further studies are needed to evaluate the use of tissue adhesives for more complex lacerations, or use in locations which have been excluded in prior research (over joints, scalp).

# ACKNOWLEDGEMENTS

The reviewers would like to thank

\* Natasha Wiebe and Ellen Crumley for their work on prior versions of this review.

\* E. Andrea Nelson, Sally Bell-Syer, Wendy Taylor and Ruth Foxlee from the Cochrane Review Wounds Group for their assistance.

\* Kirsten Lone Jensen (Trials Search Coordinator, Administrator, The Nordic Cochrane Centre) for translation of the Danish study (Schultz 1979).

\* Cochrane Review Wounds Group referees (Peter Moore, Liz Scanlon, Annette Wysocki, Sheila Benton-Jones), Editors (Nicky Cullum & David Margolis), and Statistician (Seokyung Hahn) for their comments to improve the review.

## REFERENCES

#### References to studies included in this review

#### Barnett 1998 {published and unpublished data}

\* Barnett P, Jarman FC, Goodge J, Silk G, Aickin R. Randomised trial of histoacryl blue tissue adhesive glue versus suturing in the repair of paediatric lacerations. *Journal of Paediatrics and Child Health* 1998;**34**(6):548–50. Jarman FC, Holmes A, Aickin R, Goodge G, Silk G, Barnett P. Randomised Trial of n-Butyl-2-Cyanoacrylate tissue adhesive glue vs suturing for the repair of paediatric lacerations. *Emergency Medicine* 1994;**6**(4):339. Jarman FC, Holmes A, Aickin R, Goodge G, Silk G, Barnett P. Randomised Trial of n-Butyl-2-Cyanoacrylate tissue adhesive glue vs suturing for the repair of paediatric lacerations. *Journal of Paediatrics and Child Health* 1994; **30**:A17.

# Bruns 1998 {published data only}

\* Bruns TB, Robinson BS, Smith RJ, Kile DL, Davis TP, Sullivan KM, Quinn JV. A new tissue adhesive for laceration repair in children. *Journal of Pediatrics* 1998;**132** (6):1067–70.

#### Goktas 2002 {published data only}

\* Goktas N, Karcioglu O, Coskun F, Karaduman S, Menderes A. Comparison of tissue adhesive and suturing in the repair of lacerations in the emergency department.[erratum appears in Eur J Emerg Med. 2002 Dec;9(4):360.]. *European Journal of Emergency Medicine* 2002;**9**(2):155–8.

#### Holger 2004 {published and unpublished data}

\* Holger JA, Wandersee SC, Hale DB. Cosmetic outcomes of facial lacerations repaired with tissue-adhesive, absorbably, and nonabsorbable sutures. *American Journal of Emergency Medicine* 2004;**22**(4):254–7.

#### Mattick 2002a {published data only}

\* Mattick A, Clegg G, Beattie T, Ahmad T. A randomised, controlled trial comparing a tissue adhesive (2octylcyanoacrylate) with adhesive strips (Steristrips) for paediatric laceration repair. *Emergency Medicine Journal* 2002;**19**(5):405–7.

#### Osmond 1999a {published and unpublished data}

\* Osmond MH, Quinn JV, Sutcliffe T, Jarmuske M, Klassen TP. A randomized, clinical trial comparing butylcyanoacrylate with octylcyanoacrylate in the management of selected pediatric facial lacerations. *Academic Emergency Medicine* 1999;6(3):171–7.

#### Quinn 1993 {published data only}

\* Quinn JV, Drzewiecki A, Li MM, Stiell IG, Sutcliffe T, Elmslie TJ, et al.A randomized, controlled trial comparing a tissue adhesive with suturing in the repair of pediatric facial lacerations. *Annals of Emergency Medicine* 1993;**22**(7): 1130–5.

#### Quinn 1998a {published data only}

Quinn J, Wells G, Sutcliffe T, Jarmuske M, Maw J, Stiell I, Johns P. A randomized trial comparing octylcyanoacrylate

tissue adhesive and sutures in the management of lacerations [see comments]. *JAMA* 1997;**277**(19):1527–30.

\* Quinn J, Wells G, Sutcliffe T, Jarmuske M, Maw J, Stiell I, Johns P. Tissue adhesive versus suture wound repair at 1 year: randomized clinical trial correlating early, 3-month, and 1-year cosmetic outcome. *Annals of Emergency Medicine* 1998;**32**(6):645–9.

#### Schultz 1979 {published data only}

\* Schultz A, Olesgaard P. [Tissue glue in minor skin lesions. A prospective controlled comparison between tissue glue and the suturing of skin minor lesions]. *Ugeskrift for Laeger* 1979;**141**(45):3106–7.

#### Simon 1997 {published data only}

Bruns TB, Simon HK, McLario DJ, Sullivan KM, Wood RJ, Anand KJ. Laceration repair using a tissue adhesive in a children's emergency department. *Pediatrics* 1996;**98**(4 Pt 1):673–5.

\* Simon HK, McLario DJ, Bruns TB, Zempsky WT, Wood RJ, Sullivan KM. Long-term appearance of lacerations repaired using a tissue adhesive. *Pediatrics* 1997;**99**(2): 193–5.

Simon HK, Zempsky WT, Bruns TB, Sullivan KM. Lacerations against Langer's lines: to glue or suture?. *Journal* of Emergency Medicine 1998;**16**(2):185–9.

#### Singer 1998 {published data only}

Hollander JE, Singer AJ. Application of tissue adhesives: rapid attainment of proficiency. Stony Brook Octylcyanoacrylate Study Group. *Academic Emergency Medicine* 1998;**5**(10):1012–7.

\* Singer AJ, Hollander JE, Valentine SM, Turque TW, McCuskey CF, Quinn JV. Prospective, randomized, controlled trial of tissue adhesive (2-octylcyanoacrylate) vs standard wound closure techniques for laceration repair. Stony Brook Octylcyanoacrylate Study Group. *Academic Emergency Medicine* 1998;5(2):94–9.

## Singer 2003 {published data only}

\* Singer AJ, Giordano P, Fitch JL, Gulla J, Ryker D, Chale S. Evaluation of a new high-viscosity octylcyanoacrylate tissue adhesive for laceration repair: A randomized, clinical trial. *Academic Emergency Medicine* 2003;**10**(10):1134–7.

#### Zempsky 2001 {published data only}

Zempsky WT, Grem C, Nichols J, Parrotti D. Prospective Comparison of Cosmetic Outcomes of Simple Facial Lacerations Closed with Steri-Strips or Dermabond. *Academic Emergency Medicine* 2001;**8**(5):438. \* Zempsky WT, Parrotti D, Grem C, Nichols J. Randomized controlled comparison of cosmetic outcomes of simple facial lacerations closed with Steri Strip skin closures or Dermabond tissue adhesive. *Pediatric Emergency Care* 2004; **20**(8):519–24.

#### References to studies excluded from this review

#### Alamouti 1998 {published data only}

\* Alamouti D, von Kobyiciski G, Herde M, Allard P, HoffmannK, Altmeyer P. Octylcyanoacrylate tissue adhesive in the management of laceration closure in skin cancer. *Journal of the European Academy of Dematology and Venereology* 1998;**11**:S213.

## Bernard 2001 {published data only}

\* Bernard L, Doyle J, Friedlander SF, Eichenfield LF, Gibbs NF, Cunningham BB. A prospective comparison of octyl cyanoacrylate tissue adhesive (dermabond) and suture for the closure of excisional wounds in children and adolescents. *Archives of Dermatology* 2001;**137**(9):1177–80.

#### Brown 1997 {published data only}

\* Brown V. Laceration repair with tissue adhesive in children. *Journal of Family Practice* 1997;**44**(5):445–6.

#### Charters 2000 {published data only}

\* Charters A. Wound glue: a comparative study of tissue adhesives. Accident and Emergency Nursing 2000;8(4): 223–7.

#### Doraiswamy 2003 {published and unpublished data}

Doraiswamy NV, Baig H, Hammett S, Hutton M. Which tissue adhesive for wounds?. *Injury, International Journal of the Care of the Injured* 2003;**34**(8):564–7.

## Eaglstein 2002 {published data only}

\* Eaglstein WH, Sullivan TP, Giordano PA, Miskin BM. A liquid adhesive bandage for the treatment of minor cuts and abrasions. *Dermatologic Surgery* 2002;**28**(3):263–7.

#### Farris 1981 {published data only}

\* Farris RS, Hays LV. Controlled trial of the effectiveness of randomized wound closures. *Missouri Medicine* 1981;**78** (1):17–20.

#### Fatovich 1995 {published data only}

\* Fatovich DM, Jacobs IG. A randomized, controlled trial of oral midazolam and buffered lidocaine for suturing lacerations in children (the SLIC Trial). *Annals of Emergency Medicine* 1995;**25**(2):209–14.

#### Giovannacci 2002 {published data only}

\* Giovannacci L, Eugster T, Stierli P, Hess P, Gurke L. Does fibrin glue reduce complications after femoral artery surgery? A randomised trial. *European Journal of Vascular and Endovascular Surgery* 2002;**24**(3):196–201.

#### Giri 2004 {published data only}

\* Giri P, Kanti Das M, Majumdar A. Management of different types of wound by cyanoacrylate glue fixation: A random study of 213 patients. *Journal of the Indian Medical Assocation* 2004;**102**(11):625–6.

#### Greene 1999 {published data only}

\* Greene D, Koch RJ, Goode RL. Efficacy of octyl-2cyanoacrylate tissue glue in blepharoplasty. A prospective controlled study of wound-healing characteristics. *Archives* of Facial Plastic Surgery 1999;1(4):292–6.

#### Hock 2002 {published data only}

\* Hock MO, Ooi SB, Saw SM, Lim SH. A randomized controlled trial comparing the hair apposition technique with tissue glue to standard suturing in scalp lacerations

(HAT study). *Annals of Emergency Medicine* 2002;**40**(1): 19–26.

#### Liebelt 1997 {published data only}

\* Liebelt EL. Current concepts in laceration repair. *Current Opinion in Pediatrics* 1997;**9**(5):459–64.

#### Ludlow 2000 {published data only}

\* Ludlow JB, Kutcher MJ, Samuelson A. Intraoral digital imaging documenting recurrent aphthous ulcer healing in 2-octyl cyanoacrylate versus sham-treated lesions. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics* 2000;**89**(4):425–31.

# Mattick 2002b {published data only}

\* Mattick A. Use of tissue adhesives in the management of paediatric lacerations. *Emergency Medicine Journal* 2002;**19** (5):382–5.

#### Quinn 2003 {published data only}

\* Quinn J, Cummings S, Callaham M, Sellers K. Conservative treatment reduced pain and was as effective as sutures in hand lacerations. *The Journal of Bone and Joint Surgery. American Volume* 2003;**85-A**(5):974.

#### Qureshi 1997 {published data only}

\* Qureshi A, Drew PJ, Duthie GS, Roberts AC, Monson JR. n-Butyl cyanoacrylate adhesive for skin closure of abdominal wounds: preliminary results. *Annals of the Royal College of Surgeons of England* 1997;**79**(6):414–5.

## Saxena 1999 {published data only}

\* Saxena AK, Willital GH. Octylcyanoacrylate tissue adhesive in the repair of pediatric extremity lacerations. *American Surgeon* 1999;**65**(5):470–2.

#### Singer 2002 {published data only}

\* Singer AJ, Quinn JV, Clark RE, Hollander JE, TraumaSeal Study Group. Closure of lacerations and incisions with octylcyanoacrylate: a multicenter randomized controlled trial. *Surgery* 2002;**131**(3):270–6.

Singer AJ, Quinn JV, Hollander JE. Comparison of Octylcyanoacrylate and Standard Wound Closure Methods for Lacerations and Incisions: A Multi-center Trial. *Academic Emergency Medicine* 2001;**8**(5):538.

#### Sportsmed 1997 {published data only}

\* Skin Wounds: To Glue or Not to Glue?. The Physician and Sportsmedicine 1997; Vol. 25, issue 5:18, 22.

#### Stuart 1999 {unpublished data only}

\* Stuart, J. PRCT comparing staples with glue for scalp lacerations. http://www.nrr.nhs.uk/ViewDocument.asp? ID=N0155009284 1999.

#### Sutton 1985 {published data only}

\* Sutton R, Pritty P. Use of sutures or adhesive tapes for primary closure of pretibial lacerations. *British Medical Journal (Clinical research ed.)* 1985;**290**(6482):1627.

#### Symeonoglou 1998 {published data only}

\* Symeonoglou G, Songra A. Comparison of sutures and tissue adhesives in the treatment of facial lacerations: a clinical trial [abstract]. *Journal of Cranio Maxillo Facial Surgery* 1998;**26**(Suppl 1):187.

# Additional references

#### Altman 1996

Altman DG, Bland JM. Statistics Notes: Detecting skewness from summary information. *BMJ* 1996;**313**:1200.

#### Applebaum 1993

Applebaum JS, Zalut T, Applebaum D. The use of tissue adhesion for traumatic laceration repair in the emergency department. *Annals of Emergency Medicine* 1993;**22**(7): 1190–2.

#### Coulthard 2004

Coulthard P, Worthington HV, Esposito M, van der Elst M, van Waes OJF. Tissue adhesives for closure of surgical incisions. *Cochrane Database of Systematic Reviews* 2002, Issue 3. [Art. No.: CD004287. DOI: 10.1002/ 14651858.CD004287.pub2]

#### Deeks 2001

Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). *Systematic reviews in health care*. 2nd Edition. London, UK: BMJ Book, 2001:300.

#### DerSimonian 1986

DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials* 1986;7(3):177–88.

#### Egger 1997

Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**:629–34.

#### Elmasalme 1995

Elmasalme FN, Matbouli SA, Zuberi MS. Use of tissue adhesive in the closure of small incisions and lacerations. *Journal of Pediatric Surgery* 1995;**30**(6):837–8.

#### Goodman 1994

Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. *Annals of Internal Medicine* 1994;**121**(3):200–6.

#### Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**: 557–60.

#### Higgins 2005

Higgins JPT, Green S, eds. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] Appendix 5b. http://www.cochrane.org/resources/handbook/hbook.htm (accessed October 17 2007).

#### Hollander 1995a

Hollander JE, Singer AJ, Valentine S, Henry MC. Wound registry: development and validation [published erratum appears in Annals of Emergency Medicine 1995;26(4):532]. *Annals of Emergency Medicine* 1995;25(5):675–85.

#### Hollander 1995b

Hollander JE, Blasko B, Singer AJ, Valentine S, Thode HC, Jr, Henry MC. Poor correlation of short- and long-term cosmetic appearance of repaired lacerations. *Academic Emergency Medicine* 11–1–1995;**2**(11):983–7.

#### Hollander 1999

Hollander JE, Singer AJ. Laceration management. *Annals of Emergency Medicine* 1999;**34**(3):356–67.

#### Jadad 1996

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. *Controlled Clinical Trials* 1996;**17**(1):1–12.

#### Mizrahi 1988

Mizrahi S, Bickel A, Ben-Layish E. Use of tissue adhesives in the repair of lacerations in children. *Journal of Pediatric Surgery* 1988;**23**(4):312–3.

#### Morton 1988

Morton RJ, Gibson MF, Sloan JP. The use of histoacryl tissue adhesive for the primary closure of scalp wounds. *Archives of Emergency Medicine* 1988;**5**(2):110–2.

#### Osmond 1995

Osmond MH, Klassen TP, Quinn JV. Economic comparison of a tissue adhesive and suturing in the repair of pediatric facial lacerations. *Journal of Pediatrics* 1995;**126**(6):892–5.

#### Osmond 2000

Osmond MH. Wound repair and tissue adhesives. In: Moyer VA, Elliott EJ, Davis RL, Gilbert R, Klassen T, Logan S, Mellis C, Williams K editor(s). *Evidence Based Pediatrics and Child Health.* 1st Edition. London: BMJ Books, 2000.

#### Oxman 1992

Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. *Annals of Internal Medicine* 1992;**116**:78–84.

#### Perron 2000

Perron AD, Garcia JA, Parker Hays E, Schafermeyer R. The efficacy of cyanoacrylate-derived surgical adhesive for use in the repair of lacerations during competitive athletics. *American Journal of Emergency Medicine* 2000;**18**(3):261–3.

#### Quinn 1995

Quinn JV, Drzewiecki AE, Stiell IG, Elmslie TJ. Appearance scales to measure cosmetic outcomes of healed lacerations. *American Journal of Emergency Medicine* 1995;**13**(2): 229–31

#### Quinn 1998b

Quinn JV. *Tissue Adhesives in Wound Care*. Hamilton: B.C. Decker Inc., 1998.

#### Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;**273**(5):408–12.

#### Sells 1999

Sells L, Mihalov L. Topical anesthetics and tissue adhesives: a new generation in pediatric wound management. *Pediatric Emergency Medicine Reports* 1999;4(9):1–10.

Tissue adhesives for traumatic lacerations in children and adults (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#### Sibert 1981

Sibert JR, Maddocks GB, Brown BM. Childhood accidents--an endemic of epidemic proportion. *Archives of Disease in Childhood* 1981;**56**(3):225–7.

#### SIGN

Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html# random (accessed 17 October 2007).

#### Watson 1989

Watson DP. Use of cyanoacrylate tissue adhesive for closing facial lacerations in children [see comments]. *British medical Journal (Clinical Research Ed )* 1989;**299**(6706):1014.

#### Zempsky 2005

Zempsky WT, Zehrer CL, Lyle CT, Hedbloom EC. Economic comparison of methods of wound closure: would closure strips vs. sutures and wound adhesives. *International Wound Journal* 2005;**2**(3):272–81.

# References to other published versions of this review

#### Farion 2003

Farion KJ, Osmond MH, Hartling L, Russell KF, Klassen TP, Crumley E, Wiebe N. Tissue adhesives for traumatic lacerations: A systematic review of randomized controlled trials. *Academic Emergency Medicine* 2003;**10**(2):110–8.

\* Indicates the major publication for the study

# CHARACTERISTICS OF STUDIES

# Characteristics of included studies [ordered by study ID]

# Barnett 1998

Methods	RCT of 163 enrolled lacerations. Cosmetic follow-up in 40% at 3 months and 39% at 1 year	
Participants	Children > 4 yrs with acute lacerations < 5 cm in length, not requiring deep sutures. All body areas except eyelids, mucous membranes, and joints	
Interventions	BCA $(n = 83)$ versus sutures $(n = 80)$ .	
Outcomes	Cosmesis: photographs at 3 and 12 months evaluated by 2 blinded observers using 5-point categorical scale. Pain: VAS by MD, RN, and parent with categorical FACES score by patient (not used). Complications: redness, discharge,dehiscence	
Notes	Jadad = 1; Funding = B. Braun Company Pty Ltd.; 5-point categorical scale combined with WES by using 4/5 and 5/5= 6/6 "optimal" scoring; Breakdown of scores by location and clarification of reported complication rates provided by the author	
Risk of bias		
Item	Authors' judgement Description	
Allocation concealment?	Unclear	B - Unclear
Bruns 1998		
Methods	RCT of 85/113 eligible lacerations on 83 patients (randomized by patient). Cosmetic follow-up in 79% at 3 months	
Participants	Children > 1 yr with acute lacerations, including those requiring deep sutures. All areas except scalp and mucous membranes	
Interventions	OCA (n = 42) versus standard wound care (n = 43, with 42 receiving sutures and 1 stapled)	
Outcomes	Cosmesis: photograph at 3 months rated by 2 blinded plastic surgeons using CVAS. Pain: VAS by parent. Complications: infection, dehiscence	
Notes	Jadad = 2; Funding = Closure Medical Corp; Breakdown of cosmesis by locations, need for deep sutures not available from author	
Risk of bias		
Item	Authors' judgement Description	
Allocation concealment?	Unclear B - Unclear	

Methods	RCT of 92 patients with lacerations. Cosmetic follow-up reported for 57% of patients at 3 months	
Participants	Adults with lacerations < 5cm not crossing joints or high-tension areas	
Interventions	BCA versus standard wound care (sutures).	
Outcomes	Cosmesis: assessment at 10 days and 90 days by blinded plastic surgeon using CVAS. Satisfaction: patient and MD asked if satisfied. Costs: estimated. Complications: infection	
Notes	Jadad = 3; Funding = Unknown; n in each original group, location of wounds, use of deep sutures not known. Results only for those completing 90 day follow-up	
Risk of bias		
Item	Authors' judgement	Description
Allocation concealment?	Unclear	B - Unclear
Holger 2004 Methods	Three-arm RCT of 150/230 eligible patients. 5 pat months	ients withdrew. Cosmetic follow-up in 56% at 9-12
Participants	Patients >5yrs with acute facial lacerations, including those determined before randomization to require deep sutures. Excludes scalp, ear, mucous membranes	
1		
Interventions	deep sutures. Excludes scalp, ear, mucous membran	
	deep sutures. Excludes scalp, ear, mucous membran OCA ( $n = 49$ ) versus absorbable suture ( $n = 47$ ) ver combined with data provided by author	es sus non absorbable suture (n = 49). Two suture arms 9-12 months; patient/parent completed CVAS on
Interventions	deep sutures. Excludes scalp, ear, mucous membran OCA (n = 49) versus absorbable suture (n = 47) ver combined with data provided by author Cosmesis: CVAS by 2 blinded MD's in person at satisfaction with wound. Complications: dehiscence	es sus non absorbable suture (n = 49). Two suture arms 9-12 months; patient/parent completed CVAS on e and infection ndation; Author correspondence provided combined
Interventions Outcomes	deep sutures. Excludes scalp, ear, mucous membran OCA (n = 49) versus absorbable suture (n = 47) ver combined with data provided by author Cosmesis: CVAS by 2 blinded MD's in person at satisfaction with wound. Complications: dehiscence Jadad = 3; Funding = Health Partners Research Fou	es sus non absorbable suture (n = 49). Two suture arms 9-12 months; patient/parent completed CVAS on e and infection ndation; Author correspondence provided combined
Interventions Outcomes Notes	deep sutures. Excludes scalp, ear, mucous membran OCA (n = 49) versus absorbable suture (n = 47) ver combined with data provided by author Cosmesis: CVAS by 2 blinded MD's in person at satisfaction with wound. Complications: dehiscence Jadad = 3; Funding = Health Partners Research Fou	es sus non absorbable suture (n = 49). Two suture arms 9-12 months; patient/parent completed CVAS on e and infection ndation; Author correspondence provided combined

# Mattick 2002a

Methods	RCT of 60 enrolled patients. 6 patients failed study enrolment (4 OCA failures, 1 adhesive strip failure, 1 camera failure). Cosmetic follow-up in 73% between 3 and 12 months. All results limited to those for patients that completed follow-up		
Participants	Children 1-14 yrs with acute lacerations < 5 cm in length, not requiring deep sutures or local anaesthetic for cleaning. All body areas except mucous membranes, scalp or areas of high tension		
Interventions	OCA ( $n = 30$ ) versus adhesive strips ( $n = 30$ ).		
Outcomes	Cosmesis: photographs at 3-12 months, compared to pre-repair photos, by blinded plastic surgeon using CVAS. Parents also provided assessment of scar with CVAS. Pain/Distress: VAS by parent . Ease: VAS by MD/RN doing procedure. Complications: screened for at 7-day patient review		
Notes	Jadad = 2; Funding = Unknown; Camera and Dermabond adhesive supplied by Ethicon; Parental CVAS not used as blinded assessment at the same time available. Breakdown of location not available. All CVAS scores from 3-12 months combined with other studies with late (9-12 months) assessments, as no indication of when the majority of assessments were made was given		
Risk of bias			
Item	Authors' judgement Description		
Allocation concealment?	Unclear B - Unclear		
Osmond 1999a			
Methods	RCT of 94/124 eligible lacerations. Cosmetic follow-up in 88% at 3 months		
Participants	Children < 18 yrs with acute facial lacerations < 4cm, not requiring deep sutures. Excludes scalp, ear, mucous membranes		
Interventions	OCA (n = 47) versus BCA (n = 47).		
Outcomes	Cosmesis: WES by blinded RN at 10-14 days and 3 months. Photograph at 3 months evaluated by blinded plastic surgeon on 2 occasions using CVAS. Time: recorded by MD. Ease: VAS by MD. Pain: VAS by patient (>7 yrs) or parent (<7 yrs). Complications: infection, dehiscence		
Notes	Jadad=3; Funding= Closure Medical Corp; Ease not used due to insufficient data		
Risk of bias	Risk of bias		
Item	Authors' judgement Description		
Allocation concealment?	Yes A - Adequate		

# Quinn 1993

-		
Methods	RCT of 81/90 eligible lacerations. Cosmetic follow-up in 93% at 3 months	
Participants	Children <18 yrs with facial lacerations < 4 cm, not requiring deep sutures. Excludes mucous membranes, hair-covered areas	
Interventions	BCA $(n = 41)$ versus sutures $(n = 40)$ .	
Outcomes	Cosmesis: Photograph taken at 3 months evaluated by 2 blinded plastic surgeons on 2 occasions using 3- point categorical scale and CVAS. Time: recorded by MD. Pain: VAS by parent. Complications: infection, dehiscence, erythema	
Notes	Jadad= 2; Funding= Children's Hospital of Eastern Ontario Research Institute; 3-point scale data not combined with WES	
Risk of bias		
Item	Authors' judgement	Description
Allocation concealment?	Unclear	B - Unclear
Quinn 1998a		
Methods	RCT (computer generated, stratified for facial versus non-facial) of 136/179 eligible lacerations on 130 patients (randomized by laceration allowing cross-over). Cosmetic follow-up in 72% at 3 months and 57% at 1 year	
Participants	Adults with lacerations of any length, including those requiring deep sutures. All body areas except ear, scalp, mucous membrane, joints, hands or feet	
Interventions	OCA ( $n = 68$ ) versus sutures ( $n = 68$ ).	
Outcomes	Cosmesis: WES by 2 RN's (one blinded) at 3-10 days, 3 and 12 months. Photos at 3 and 12 months rated by blinded plastic surgeon on 2 occasions using CVAS. Time: recorded by MD. Pain: VAS by patient. Complications: infection, dehiscence, need for delayed closure or revision	
Notes	Jadad = 3; Funding = Closure Medical Corp; Breakdown of cosmesis by location, need for deep sutures not available from author	
Risk of bias		

Nor of our		
Item	Authors' judgement	Description
Allocation concealment?	Unclear	B - Unclear

100 consecutive patients randomized by sealed envelope method. 11 patients withdrew	
Patients of all ages with acute simple lacerations to the face < 5 cm in length, not requiring deep sutures	
BCA ( $n = 50$ ) versus sutures ( $n = 50$ ).	
Cosmesis: Acceptable (good healing without diastasis or infection) versus Unacceptable as judged at 7 and 30 days. Complications: diastasis, infection, allergic reaction or skin discoloration	
Jadad = 2; Funding = unknown; Translated from Danish; Acceptable/Unacceptable scoring combined with WES with Acceptable = 6/6 "optimal"; Breakdown of cosmesis by age, need for deep sutures not available from author	
Authors' judgement	Description
Unclear	B - Unclear
RCT of 61 eligible lacerations. Cosmetic follow-up in 90% at 2 months and 52% at 1 year	
Children 1-18 yrs with acute lacerations < 5 cm in length, including those requiring deep sutures. All body areas except ear, mucous membranes and joints	
BCA ( $n = 30$ ) versus sutures ( $n = 31$ ).	
BCA ( $n = 30$ ) versus sutures ( $n = 31$ ).	
	blinded plastic surgeons using CVAS. Time: recorded cion, dehiscence
Cosmesis: photograph at 2 and 12 months rated by 2 by MD. Pain: VAS by parent. Complications: infect	
Cosmesis: photograph at 2 and 12 months rated by 2 by MD. Pain: VAS by parent. Complications: infect Jadad = 1; Funding = unknown; Breakdown of cosm	cion, dehiscence
Cosmesis: photograph at 2 and 12 months rated by 2 by MD. Pain: VAS by parent. Complications: infect Jadad = 1; Funding = unknown; Breakdown of cosm	cion, dehiscence
	Patients of all ages with acute simple lacerations to the BCA (n = 50) versus sutures (n = 50).         Cosmesis: Acceptable (good healing without diastasis 30 days. Complications: diastasis, infection, allergiced Jadad = 2;         Funding = unknown; Translated from Danish; Acceptable = 6/6 "optimal"; Breakdown of cost author         Authors' judgement         Unclear         RCT of 61 eligible lacerations. Cosmetic follow-up         Children 1-18 yrs with acute lacerations < 5 cm interval

# Singer 1998

Methods	RCT (block randomized for deep suture vs no deep suture) of 124 eligible lacerations. Cosmetic follow- up in 94% at 3 months	
Participants	Patients of all ages (>1 yr) with acute lacerations, including those requiring deep sutures. All body areas except mucous membrane and hair-covered areas	
Interventions	OCA ( $n = 63$ ) versus standard wound care ( $n = 61$ with 54 receiving sutures, 1 stapled and 6 closed with adhesive strips)	
Outcomes	Cosmesis: WES by another blinded MD at 3 months; patient completed CVAS on satisfaction with wound. Complications: infection, dehiscence	
Notes	Jadad = 1; Funding = Closure Medical Corp; Patient satisfaction CVAS combined with other blinded CVAS since it is the true "Gold Standard" for cosmetic outcome. Breakdown of cosmesis by age, location, need for deep sutures not available from author	
Risk of bias		
Item	Authors' judgement Description	
Allocation concealment?	Unclear B - Unclear	
Singer 2003		
Methods	RCT of 84 patients. No cosmesis outcome measures.	
Participants	Patients >1yr with acute lacerations amenable to tissue adhesive closure. Excludes scalp and mucocutaneous areas	
Interventions	High-viscosity OCA (n = 42) versus regular OCA (n = 42).	
Outcomes	Complications: migration of tissue adhesive >1cm from the wound margins	
Notes	Jadad = 2; Funding = Closure Medical Corp.; No subgroup data for age or location is available. No other outcomes were recorded	
Risk of bias		
Item	Authors' judgement Description	
Allocation concealment?	Yes	A - Adequate

# Zempsky 2001

Item	Authors' judgement	Description
Risk of bias		
Notes	Jadad = 3; Funding = 3M Inc.; Initially included abstract data updated to data reported in full publication; Breakdown of pain scores for those from parent versus those from child not available from author	
Outcomes	Cosmesis: photograph at 2 months evaluated by 2 blinded plastic surgeons using CVAS. Pain: VAS by either parent or child. Complications: infection, dehiscence	
Interventions	OCA ( $n = 49$ ) versus adhesive strips ( $n = 48$ )	
Participants	Children (1-18 yrs) with simple facial lacerations not requiring deep sutures. Wounds in high-tension or mobile areas were avoided	
Methods	RCT of 100 lacerations. 3 patients later excluded as non-facial lacerations. Cosmetic follow-up in 85% at 2 months	

Itelli	Rations Judgement	Description
Allocation concealment?	Yes	A - Adequate

BCA: Butylcyanoacrylate or Histoacryl Blue CVAS: Cosmetic Visual Analogue Scale ENB: Enbucrylate or Indermil FACES: a categorical pain scale (see reference Bieri 1990) MD: Doctor OCA: Octylcyanoacrylate or Dermabond RCT: Randomised Controlled Trial RN: Registered Nurse VAS: Visual Analogue Scale WES: Wound Evaluation Score n=number of lacerations in each treatment arm

# Characteristics of excluded studies [ordered by study ID]

Reason for exclusion
Study of wound closure after surgical excision of skin cancers, no traumatic lacerations
Study of incisions, not lacerations.
Journal Club review of Simon's article reporting 1 yr follow-up on BCA versus suture
Study not randomized ("Consecutively assigned").

# (Continued)

Doraiswamy 2003	Study not described as randomized ; study outcomes very subjective or not combinable with other outcomes
Eaglstein 2002	Study deals with abrasions, not lacerations and compares a liquid bandage product to traditional band-aids
Farris 1981	Study is not randomized, nor does it deal with lacerations or tissue adhesives
Fatovich 1995	Study deals with sedation/analgesia for laceration repair, not the product used for the repair
Giovannacci 2002	Study does not deal with lacerations or tissue adhesives.
Giri 2004	Observational study with no comparison arm.
Greene 1999	Study deals with surgical incisions.
Hock 2002	Study deals with tissue adhesive for scalp lacerations, though the method that the adhesive is used is not standard. As well, because the laceration was in an area covered with hair, no cosmetic assessment was made beyond 7 days, and all assessments of healing/complications were not completed in a blinded fashion
Liebelt 1997	Summary article on tissue adhesives in children
Ludlow 2000	Study deals with aphthous ulcers.
Mattick 2002b	Review article.
Quinn 2003	Study deals with suturing versus conservative treatment of hand lacerations
Qureshi 1997	Study is not randomized and deals with surgical incisions.
Saxena 1999	All patients with high tension lacerations across joints. Lacerations treated with tissue adhesive or suture, then splinted to reduce tension
Singer 2002	Multi-centered study has 10 sites, of which 4 sites deal with lacerations. Results from 2 of the sites have previously been independently published and included in the original review. (See BRUNS 1998 and SINGER 1998). Attempts to obtain unpublished data from the remaining 2 sites have been unsuccessful
Sportsmed 1997	Highlights of Simon's article reporting 1 yr follow-up on BCA versus suture
Stuart 1999	Trial listed in on-line trial register. All attempts to contact author for more information about the status of the trial/data were unsuccessful. No subsequent publication has been found
Sutton 1985	Study deals with suture versus adhesive strips.
Symeonoglou 1998	Abstract of study, but without any results. All attempts to contact the authors to determine the status of the trial/results have been unsuccessful

# DATA AND ANALYSES

# Comparison 1. Tissue Adhesive versus Standard Wound Closure

Outcome or subgroup title	No. of No. of Ibgroup title studies participants		Statistical method	Effect size		
1 Cosmesis (CVAS) at 5 to 14 days	1		Mean Difference (IV, Random, 95% CI)	Subtotals only		
2 Cosmesis (CVAS) at 1 to 3 months	7	549	Mean Difference (IV, Random, 95% CI)	1.62 [-3.17, 6.41]		
3 Cosmesis (CVAS) at 9 to 12 months	4	237	Mean Difference (IV, Fixed, 95% CI)	1.48 [-3.10, 6.06]		
4 Cosmesis (WES, Other) at 5 to 14 days	2	195	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.87, 1.09]		
5 Cosmesis (WES, Other) at 1 to 3 months	4	364	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.89, 1.11]		
6 Cosmesis (WES, Other) at 9 to 12 months	2	140	Risk Ratio (M-H, Fixed, 95% CI)	1.08 [0.89, 1.30]		
7 Cosmesis (CVAS) at 5 to 14 days by age	1		Mean Difference (IV, Random, 95% CI)	Totals not selected		
7.1 Pediatric (<18)	0		Mean Difference (IV, Random, 95% CI)	Not estimable		
7.2 Adult (=> 18)	1		Mean Difference (IV, Random, 95% CI)	Not estimable		
8 Cosmesis (CVAS) at 1 to 3 months by age	6	433	Mean Difference (IV, Random, 95% CI)	1.71 [-4.20, 7.63]		
8.1 Pediatric (<18)	4	283	Mean Difference (IV, Random, 95% CI)	1.25 [-8.58, 11.08]		
8.2 Adult (=> 18)	2	150	Mean Difference (IV, Random, 95% CI)	2.41 [-5.43, 10.26]		
9 Cosmesis (CVAS) at 9 to 12 months by age	4	237	Mean Difference (IV, Fixed, 95% CI)	2.17 [-2.18, 6.51]		
9.1 Pediatric (<18)	3	92	Mean Difference (IV, Fixed, 95% CI)	2.50 [-4.78, 9.78]		
9.2 Adult (=> 18)	2	145	Mean Difference (IV, Fixed, 95% CI)	1.98 [-3.43, 7.39]		
10 Cosmesis (WES, Other) at 5 to14 days by age	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected		
10.1 Pediatric (<18)	0		Risk Ratio (M-H, Random, 95% CI)	Not estimable		
10.2 Adult (=>18)	1		Risk Ratio (M-H, Random, 95% CI)	Not estimable		
11 Cosmesis (WES, Other) at 1 to 3 months by age	2	170	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.77, 1.21]		
11.1 Pediatric (<18)	1	65	Risk Ratio (M-H, Random, 95% CI)	1.0 [0.38, 2.65]		
11.2 Adult (=>18)	1	105	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.77, 1.22]		
12 Cosmesis (WES, Other) at 9 to 12 months by age	2	140	Risk Ratio (M-H, Random, 95% CI)	1.10 [0.86, 1.42]		
12.1 Pediatric (<18)	1	63	Risk Ratio (M-H, Random, 95% CI)	1.18 [0.70, 1.98]		
12.2 Adult (=>18)	1	77	Risk Ratio (M-H, Random, 95% CI)	1.08 [0.81, 1.45]		
13 Cosmesis (CVAS) at 5 to 14 days by location	0		Mean Difference (IV, Random, 95% CI)	Totals not selected		
13.1 Face	0		Mean Difference (IV, Random, 95% CI)	Not estimable		
13.2 Body	0		Mean Difference (IV, Random, 95% CI)	Not estimable		
14 Cosmesis (CVAS) at 1 to 3 months by location	2		Mean Difference (IV, Random, 95% CI)	Subtotals only		
14.1 Face	2	161	Mean Difference (IV, Random, 95% CI)	-1.81 [-11.60, 7.98]		

14.2 Body	0	0	Mean Difference (IV, Random, 95% CI)	Not estimable
15 Cosmesis (CVAS) at 9 to 12	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
months by location				
15.1 Face	1		Mean Difference (IV, Random, 95% CI)	Not estimable
15.2 Body	0		Mean Difference (IV, Random, 95% CI)	Not estimable
16 Cosmesis (WES, Other) at 5 to	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
14 days by location				
16.1 Face	1		Risk Ratio (M-H, Random, 95% CI)	Not estimable
16.2 Body	0		Risk Ratio (M-H, Random, 95% CI)	Not estimable
17 Cosmesis (WES, Other) at 1 to	2	150	Risk Ratio (M-H, Fixed, 95% CI)	1.06 [0.91, 1.23]
3 months by location				
17.1 Face	2	136	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.88, 1.20]
17.2 Body	1	14	Risk Ratio (M-H, Fixed, 95% CI)	1.5 [0.61, 3.67]
18 Cosmesis (WES, Other) at 9 to	1	63	Risk Ratio (M-H, Random, 95% CI)	1.48 [0.35, 6.35]
12 months by location				
18.1 Face	1	55	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.82, 1.34]
18.2 Body	1	8	Risk Ratio (M-H, Random, 95% CI)	4.71 [0.36, 60.97]
19 Cosmesis (CVAS) at 5 to 14	0		Mean Difference (IV, Random, 95% CI)	Totals not selected
days by deep sutures				
19.1 No Deep Sutures	0		Mean Difference (IV, Random, 95% CI)	Not estimable
19.2 Deep Sutures	0		Mean Difference (IV, Random, 95% CI)	Not estimable
20 Cosmesis (CVAS) at 1 to 3	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
months by deep sutures				
20.1 No Deep Sutures	2	161	Mean Difference (IV, Random, 95% CI)	-1.81 [-11.60, 7.98]
20.2 Deep Sutures	0	0	Mean Difference (IV, Random, 95% CI)	Not estimable
21 Cosmesis (CVAS) at 9 to 12	2	116	Mean Difference (IV, Random, 95% CI)	-1.61 [-8.93, 5.71]
months by deep sutures				
21.1 No Deep Sutures	2	103	Mean Difference (IV, Random, 95% CI)	-1.61 [-8.93, 5.71]
21.2 Deep Sutures	1	13	Mean Difference (IV, Random, 95% CI)	Not estimable
22 Cosmesis (WES, Other) at 5 to	0		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
14 days by deep sutures				
22.1 No Deep Sutures	0		Risk Ratio (M-H, Random, 95% CI)	Not estimable
22.2 Deep Sutures	0		Risk Ratio (M-H, Random, 95% CI)	Not estimable
23 Cosmesis (WES, Other) at 1 to	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
3 months by deep sutures				
23.1 No Deep Sutures	1		Risk Ratio (M-H, Random, 95% CI)	Not estimable
23.2 Deep Sutures	0		Risk Ratio (M-H, Random, 95% CI)	Not estimable
24 Cosmesis (WES, Other) at 9 to	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
12 months by deep sutures				
24.1 No Deep Sutures	1		Risk Ratio (M-H, Random, 95% CI)	Not estimable
24.2 Deep Sutures	0		Risk Ratio (M-H, Random, 95% CI)	Not estimable
25 Cosmesis (CVAS) at 5 to 14	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
days by tissue adhesive				
25.1 BCA	1		Mean Difference (IV, Fixed, 95% CI)	Not estimable
25.2 OCA	0		Mean Difference (IV, Fixed, 95% CI)	Not estimable
26 Cosmesis (CVAS) at 1 to 3	7	549	Mean Difference (IV, Random, 95% CI)	1.62 [-3.17, 6.41]
months by tissue adhesive				
26.1 BCA	3	182	Mean Difference (IV, Random, 95% CI)	7.50 [1.75, 13.25]
26.2 OCA	4	367	Mean Difference (IV, Random, 95% CI)	-2.07 [-5.86, 1.72]
27 Cosmesis (CVS) at 9 to 12	4	237	Mean Difference (IV, Fixed, 95% CI)	1.48 [-3.10, 6.06]
months by tissue adhesive				

Tissue adhesives for traumatic lacerations in children and adults (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

27.1 BCA	1	32	Mean Difference (IV, Fixed, 95% CI)	10.5 [-1.30, 22.30]
27.2 OCA	3	205	Mean Difference (IV, Fixed, 95% CI)	-0.12 [-5.09, 4.85]
28 Cosmesis (WES, Other) at 5 to	2	195	Odds Ratio (M-H, Fixed, 95% CI)	0.84 [0.37, 1.89]
14 days by tissue adhesive	2	177	Ouus Ratio (M-11, 11xcu, 9970 Cl)	0.04 [0.57, 1.67]
28.1 BCA	1	89	Odds Ratio (M-H, Fixed, 95% CI)	0.71 [0.15, 3.39]
28.2 OCA	1	106	Odds Ratio (M-H, Fixed, 95% CI)	0.89 [0.34, 2.31]
29 Cosmesis (WES, Other) at 1 to	4	364	Odds Ratio (M-H, Fixed, 95% CI)	0.97 [0.58, 1.62]
3 months by tissue adhesive	т	504	Ouus Ratio (M-11, 11xcu, 9970 Cl)	0.)/ [0.)0, 1.02]
29.1 BCA	2	150	Odds Ratio (M-H, Fixed, 95% CI)	1.26 [0.52, 3.03]
29.2 OCA	2	214	Odds Ratio (M-H, Fixed, 95% CI)	0.85 [0.45, 1.60]
30 Cosmesis (WES, Other) at 9 to	2	140	Odds Ratio (M-H, Fixed, 95% CI)	1.36 [0.62, 2.95]
12 months by tissue adhesive	2	140		1.50 [0.02, 2.75]
30.1 BCA	1	63	Odds Ratio (M-H, Fixed, 95% CI)	1.46 [0.41, 5.20]
30.2 OCA	1	05 77	Odds Ratio (M-H, Fixed, 95% CI)	1.3 [0.49, 3.47]
31 Pain (VAS)	6	//	Mean Difference (IV, Random, 95% CI)	Subtotals only
31.1 Patient	1	136	Mean Difference (IV, Random, 95% CI)	-10.80 [-17.09, -4.
JIII Faticité	1	150	With Difference (17, Randolli, 7)70 Ci	51]
31.2 Parent	5	434	Mean Difference (IV, Random, 95% CI)	-13.42 [-19.99, -6.
51.2 Talent	)	F.C.F	Wear Difference (17, Kandolii, 7770 Cl)	85]
31.3 Doctor	1	163	Mean Difference (IV, Random, 95% CI)	-12.60 [-20.06, -5.
51.5 Doctor	1	105	Weat Difference (iv, Kandolii, 99% Ci)	-12.00 [-20.00, - <i>)</i> . 14]
31.4 Nurse/Other Observer	1	163	Mean Difference (IV, Random, 95% CI)	-14.90 [-22.50, -7.
51.4 Nuise/Other Observer	1	105	Weat Difference (1V, Kandolii, 99% Cf)	-14.90 [-22.90, -7. 30]
32 Time to Complete (min)	6	584	Mean Difference (IV, Random, 95% CI)	-4.66 [-7.22, -2.10]
33 Ease of Procedure (VAS)	1	704	Mean Difference (IV, Random, 95% CI)	Totals not selected
34 Complications	9		Risk Difference (M-H, Random, 95% CI)	Subtotals only
34.1 Dehiscence	8	782	Risk Difference (M-H, Random, 95% CI)	Not estimable
34.2 Infection	9	834	Risk Difference (M-H, Random, 95% CI)	Not estimable
34.3 Erythema	2	186	Risk Difference (M-H, Random, 95% CI)	-0.10 [-0.19, -0.00]
34.4 Delayed closure	1	136	Risk Difference (M-H, Random, 95% CI)	Not estimable
34.5 Discharge	1	111	Risk Difference (M-H, Random, 95% CI)	0.06 [-0.05, 0.18]
5 1.7 Discharge				0.00 [ 0.09, 0.10]

# Comparison 2. BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Cosmesis (CVAS) at 1 to 3 months	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
2 Cosmesis (WES, Other) at 5 to 14 days	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
3 Cosmesis (WES, Other) at 1 to 3 months	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
4 Pain (VAS)	1	90	Mean Difference (IV, Random, 95% CI)	4.97 [-14.76, 24.71]
4.1 Patient	1	18	Mean Difference (IV, Random, 95% CI)	16.80 [-2.05, 35.65]
4.2 Parent	1	72	Mean Difference (IV, Random, 95% CI)	-3.60 [-13.60, 6.40]
4.3 Doctor	0	0	Mean Difference (IV, Random, 95% CI)	Not estimable
4.4 Nurse/Other Observer	0	0	Mean Difference (IV, Random, 95% CI)	Not estimable
5 Time to Complete (min)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

Tissue adhesives for traumatic lacerations in children and adults (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

6 Complications	1		Risk Difference (M-H, Random, 95% CI)	Subtotals only
6.1 Dehiscence	1	93	Risk Difference (M-H, Random, 95% CI)	0.04 [-0.03, 0.11]
6.2 Infection	1	93	Risk Difference (M-H, Random, 95% CI)	Not estimable
6.3 Erythema	0	0	Risk Difference (M-H, Random, 95% CI)	Not estimable

# Comparison 3. Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Complications	1		Risk Difference (M-H, Random, 95% CI)	Subtotals only
1.1 Migration of TA > 1cm	1	84	Risk Difference (M-H, Random, 95% CI)	0.55 [0.37, 0.73]
1.2 Dehiscence	1	78	Risk Difference (M-H, Random, 95% CI)	-0.03 [-0.10, 0.04]
1.3 Infection	1	78	Risk Difference (M-H, Random, 95% CI)	Not estimable

# Analysis I.I. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome I Cosmesis (CVAS) at 5 to 14 days.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: I Cosmesis (CVAS) at 5 to 14 days

Study or subgroup	Tissue Adhesive		SWC		Mean Difference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl	IV,Random,95% CI
Goktas 2002	24	79.17 (8.8)	28	79.17 (8.81)		0.0 [ -4.80, 4.80 ]
<b>Subtotal (95% CI)</b> Heterogeneity: not applicab Test for overall effect: Z = C			0			0.0 [ 0.0, 0.0 ]
					-10 -5 0 5 10 Favours SWC Favours Tiss Adh	
Tissue adhesives for trau			•			2

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# Analysis I.2. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 2 Cosmesis (CVAS) at I to 3 months.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 2 Cosmesis (CVAS) at I to 3 months

Tissue Adhesive		SWC		Mean Difference	Weight	Mean Difference
Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	-	IV,Random,95% CI
30	51.5 (20.76)	25	36.5 (21.12)	<b>_</b>	10.9 %	5.00 [ 3.88, 26.12 ]
45	56.2 (18)	41	62.8 (20.5)		14.8 %	-6.60 [ -14.79, 1.59 ]
37	60.6 (20.15)	38	57.2 (20.15)		13.4 %	3.40 [ -5.72, 12.52 ]
50	67 (15.22)	48	68.4 (15.22)		18.5 %	-1.40 [ -7.43, 4.63 ]
35	68 (29.84)	32	75 (28.43)	·	8.1 %	-7.00 [ -20.96, 6.96 ]
61	83.8 (19.4)	55	82.5 (17.6)		17.3 %	1.30 [ -5.43, 8.03 ]
24	81.25 (13.29)	28	74.64 (12.01)		16.9 %	6.61 [ -0.32, 13.54 ]
282		267		-	100.0 %	1.62 [ -3.17, 6.41 ]
= 22.79; Chi <sup>2</sup> = 13.99	9, df = 6 (P = 0.03	); I <sup>2</sup> =57%	6			
Z = 0.66 (P = 0.51)						
	N 30 45 37 50 35 61 24 282 : 22.79; Chi <sup>2</sup> = 13.99	N         Mean(SD)           30 $51.5$ (20.76)           45 $56.2$ (18)           37 $60.6$ (20.15)           50 $67$ (15.22)           35 $68$ (29.84)           61 $83.8$ (19.4)           24 $81.25$ (13.29) <b>282</b> $22.79$ ; Chi <sup>2</sup> = 13.99, df = 6 (P = 0.03)	N         Mean(SD)         N           30 $51.5$ (20.76)         25           45 $56.2$ (18)         41           37 $60.6$ (20.15)         38           50 $67$ (15.22)         48           35 $68$ (29.84)         32           61 $83.8$ (19.4)         55           24 $81.25$ (13.29)         28           282         267           : 22.79; Chi <sup>2</sup> = 13.99, df = 6 (P = 0.03); l <sup>2</sup> = 579	N         Mean(SD)         N         Mean(SD)           30         51.5 (20.76)         25         36.5 (21.12)           45         56.2 (18)         41         62.8 (20.5)           37         60.6 (20.15)         38         57.2 (20.15)           50         67 (15.22)         48         68.4 (15.22)           35         68 (29.84)         32         75 (28.43)           61         83.8 (19.4)         55         82.5 (17.6)           24         81.25 (13.29)         28         74.64 (12.01)           282         267         22.79; Chi² = 13.99, df = 6 (P = 0.03); l² = 57%	Tissue Adhesive     SWC     Difference       N     Mean(SD)     N     Mean(SD)     IV,Random,95% CI       30     51.5 (20.76)     25     36.5 (21.12)     Image: constraint of the state of the	Tissue Adhesive       SWC       Difference       Weight         N       Mean(SD)       N       Mean(SD)       IV.Random,95% CI         30       51.5 (20.76)       25       36.5 (21.12)       IO.9 %         45       56.2 (18)       41       62.8 (20.5)       II.4.8 %         37       60.6 (20.15)       38       57.2 (20.15)       II.8.5 %         35       68 (29.84)       32       75 (28.43)       II.8.5 %         61       83.8 (19.4)       55       82.5 (17.6)       I7.3 %         24       81.25 (13.29)       28       74.64 (12.01)       I6.9 %         282       267       100.0 %       100.0 %

-20 -10 0 10 20 Favours Tiss SWC

Favours Tiss Adh

# Analysis 1.3. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 3 Cosmesis (CVAS) at 9 to 12 months.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 3 Cosmesis (CVAS) at 9 to 12 months

Study or subgroup	Tissue Adhesive		SWC			Di	Mean fference		Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		IV,Fiz	ked,95% Cl			IV,Fixed,95% CI
Holger 2004	27	81.54 (19.22)	57	81.88 (15.53)			•		30.5 %	-0.34 [ -8.64, 7.96 ]
Mattick 2002a	19	87 (19.6)	25	87 (14.3)			-		19.2 %	0.0 [ -10.44, 10.44 ]
Quinn 1998a	37	69 (19.6)	40	69 (14.3)			•		35.2 %	0.0 [ -7.72, 7.72 ]
Simon 1997	17	54.5 (19.6)	15	44 (14.3)					15.1 %	10.50 [ -1.30, 22.30 ]
Total (95% CI)	100		137				-		100.0 %	1.48 [ -3.10, 6.06 ]
Heterogeneity: Chi <sup>2</sup> =	= 2.65, df = 3 (P = 0	.45); l <sup>2</sup> =0.0%								
Test for overall effect:	Z = 0.63 (P = 0.53)									
Test for subgroup diff	erences: Not applicat	ble								
					-20	-10	0 10	20		
					Favou	rs SWC	Favours	Tiss Ad	h	

# Analysis I.4. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 4 Cosmesis (WES, Other) at 5 to 14 days.

Review: Tissue adhesiv	es for traumatic lacerations i					
Comparison: I Tissue	Adhesive versus Standard W					
Outcome: 4 Cosmesis	(WES, Other) at 5 to 14 da	ys				
Study or subgroup	Tissue Adhesive n/N	sWC n/N		Risk Ratio (ed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Quinn 1998a	42/53	43/53			50.9 %	0.98[0.81,1.18]
Schultz 1979	40/44	42/45	-	-	49.1 %	0.97 [ 0.86, 1.10 ]
<b>Total (95% CI)</b> Total events: 82 (Tissue A Heterogeneity: $Chi^2 = 0.0$ Test for overall effect: Z =	00, df = 1 (P = 0.98); $I^2 = 0.0$	<b>98</b> %			100.0 %	0.98 [ 0.87, 1.09 ]
			0.5 0.7 Favours SWC	I I.5 2 Favours Tiss Adh		
	umatic lacorations in cl		-14- ( <b>D</b>			2

# Analysis 1.5. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 5 Cosmesis (WES, Other) at 1 to 3 months.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 5 Cosmesis (WES, Other) at 1 to 3 months

Study or subgroup	Tissue Adhesive	SWC	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Barnett 1998	20/35	15/30		11.6 %	1.14 [ 0.72, 1.81 ]
Quinn 1998a	36/50	36/48		26.3 %	0.96 [ 0.76, 1.22 ]
Singer 1998	47/61	44/55		33.1 %	0.96 [ 0.80, 1.17 ]
Schultz 1979	40/42	41/43	+	29.0 %	1.00 [ 0.91, 1.10 ]
Total (95% CI)	188	176	+	100.0 %	0.99 [ 0.89, 1.11 ]
Total events: 143 (Tissue	Adhesive), 136 (SWC)				
Heterogeneity: $Chi^2 = 0.5$	55, df = 3 (P = 0.91); l <sup>2</sup> =0.0	%			
Test for overall effect: Z =	= 0.12 (P = 0.90)				
			0.5 0.7 I I.5 2		
			Favours SWC Favours Tiss Ad	h	

# Analysis I.6. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 6 Cosmesis (WES, Other) at 9 to 12 months.

Study or subgroup	Tissue Adhesive	SWC			Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,Fi	xed,95% C			M-H,Fixed,95% Cl
Barnett 1998	26/31	25/32			<b>-</b>		48.7 %	1.07 [ 0.84, 1.36 ]
Quinn 1998a	27/37	27/40		-	-		51.3 %	1.08 [ 0.81, 1.45 ]
Total (95% CI)	68	72			•		100.0 %	1.08 [ 0.89, 1.30 ]
Total events: 53 (Tissue A	dhesive), 52 (SWC)							
Heterogeneity: $Chi^2 = 0.0$	00, df = 1 (P = 0.97); $I^2 = 0.0$	)%						
Test for overall effect: Z =	= 0.77 (P = 0.44)							
			1					
			0.2	0.5	1 2	5		
			Favou	irs SWC	Favours	Tiss Adh		

Tissue adhesives for traumatic lacerations in children and adults (Review)

Review: Tissue adhesives for traumatic lacerations in children and adults Comparison: I Tissue Adhesive versus Standard Wound Closure

Copyright  $\textcircled{\sc 0}$  2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# Analysis 1.7. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 7 Cosmesis (CVAS) at 5 to 14 days by age.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 7 Cosmesis (CVAS) at 5 to 14 days by age

Study or subgroup	Tissue Adhesive		SWC		Mean Difference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	IV,Random,95% CI
l Pediatric (<18)						
2 Adult (=> 18)						
Goktas 2002	24	79.17 (8.81)	28	71.43 (9.7)		7.74 [ 2.71, 12.77 ]
					-20 -10 0 10 20	
					Favours SWC Favours Tiss Adh	

# Analysis I.8. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 8 Cosmesis (CVAS) at I to 3 months by age.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 8 Cosmesis (CVAS) at I to 3 months by age

Study or subgroup	Tissue Adhesive		SWC		Diffe	Mean erence	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Rando	om,95% Cl	-	IV,Random,95% CI
Pediatric (<18)								
Bruns 1998	35	68 (29.84)	32	75 (28.43)			10.8 %	-7.00 [ -20.96, 6.96 ]
Quinn 1993	37	60.6 (20.15)	38	57.2 (20.15)	-	-	16.5 %	3.40 [ -5.72, 12.52 ]
Simon 1997	30	51.5 (20.76)	25	36.5 (21.12)			13.9 %	15.00 [ 3.88, 26.12 ]
Zempsky 2001	45	56.2 (18)	41	62.8 (20.5)	-	_	17.9 %	-6.60 [ -14.79, 1.59 ]
Subtotal (95% CI)	147		136		-	-	<b>59.0</b> %	1.25 [ -8.58, 11.08 ]
Heterogeneity: $Tau^2 = 71$	1.66; Chi <sup>2</sup> = 10.91, dt	= 3 (P = 0.01);	l <sup>2</sup> =72%					
Test for overall effect: Z =	= 0.25 (P = 0.80)							
2 Adult (=> 18)								
Goktas 2002	24	81.25 (13.29)	28	74.64 (12.01)			19.8 %	6.61 [ -0.32, 13.54 ]
					-50 -25 (	0 25 50		
					Favours SWC	Favours Tiss A	Ndh	(Continued )
								(Continued )
Fissue adhesives for tra	aumatic laceratio	ns in children a	and adul	ts (Review)				30
Copyright © 2009 The				• •	Sons, Ltd.			

								( Continued)
Study or subgroup	Tissue Adhesive		SWC		Mi Differe	ean nce	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random	,95% CI		IV,Random,95% CI
Quinn 1998a	50	67 (15.22)	48	68.4 (15.22)			21.2 %	-1.40 [ -7.43, 4.63 ]
Subtotal (95% CI)	74		76		+		41.0 %	2.41 [ -5.43, 10.26 ]
Heterogeneity: $Tau^2 = 21$	.10; Chi <sup>2</sup> = 2.92, df =	$  (P = 0.09);  ^2$	=66%					
Test for overall effect: Z =	= 0.60 (P = 0.55)							
Total (95% CI)	221		212		+		100.0 %	1.71 [ -4.20, 7.63 ]
Heterogeneity: Tau <sup>2</sup> = 33	3.49; Chi <sup>2</sup> = 13.98, df =	= 5 (P = 0.02); I <sup>2</sup>	2 =64%					
Test for overall effect: Z =	= 0.57 (P = 0.57)							
					-50 -25 0	25 5	D	
					Favours SWC	Favours Tiss .	Adh	

# Analysis I.9. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 9 Cosmesis (CVAS) at 9 to 12 months by age.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 9 Cosmesis (CVAS) at 9 to 12 months by age

Study or subgroup	Tissue Adhesive		SWC			Mean erence	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixe	d,95% Cl		IV,Fixed,95% CI
Pediatric (<18)								
Holger 2004	8	68.74 (23.81)	8	79.85 (15.91)	• · · ·		4.8 %	-  .   [ -30.95, 8.73 ]
Mattick 2002a	19	87 (19.6)	25	87 (14.3)		<b></b>	17.3 %	0.0 [ -10.44, 10.44 ]
Simon 1997	17	54.5 (19.6)	15	44 (14.3)	-	<b>e</b> >	13.5 %	10.50 [ -1.30, 22.30 ]
Subtotal (95% CI)	44		<b>48</b>		-		35.6 %	2.50 [ -4.78, 9.78 ]
Heterogeneity: Chi <sup>2</sup> = 3: Test for overall effect: Z = 2 Adult (=> 18) Holger 2004	,	87.08 (13.89)	49	83.18 (15.42)	_		32.7 %	3.90 [ -3.69, 11.49 ]
Quinn 1998a	37	69 (19.6)	40	69 (14.3)			31.7 %	0.0 [ -7.72, 7.72 ]
Subtotal (95% CI) Heterogeneity: $Chi^2 = 0$ . Test for overall effect: Z =	50, df = 1 (P = 0.48)	<sup>12</sup> =0.0%	89				64.4 %	1.98 [ -3.43, 7.39 ]
					-20 -10 C Favours SWC	) 10 20 Favours Tiss A		(Continued)

Tissue adhesives for traumatic lacerations in children and adults (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



# Analysis 1.10. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 10 Cosmesis (WES, Other) at 5 to 14 days by age.

Review: Tissue adhesives	for traumatic lacerations in children	and adults			
Comparison: I Tissue Adl	hesive versus Standard Wound Clos	sure			
Outcome: 10 Cosmesis (\	WES, Other) at 5 to 14 days by age				
Study or subgroup	Tissue Adhesive	SWC	F	Risk Ratio M-	Risk Ratio M-
	n/N	n/N	H,Rar	ndom,95% Cl	H,Random,95% Cl_
Pediatric (<18)					
2 Adult (=>18)					
Quinn 1998a	42/53	43/53			0.98 [ 0.81, 1.18 ]
			0.5 0.7	1 1.5 2	
			Favours SWC	Favours Tiss Adh	
Tissue adhesives for traur	natic lacerations in children a	nd adults (Review)			32
Copyright © 2009 The Co	ochrane Collaboration. Publish	ed by John Wiley & So	ons, Ltd.		

# Analysis I.II. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome II Cosmesis (WES, Other) at I to 3 months by age.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: II Cosmesis (WES, Other) at I to 3 months by age

Study or subgroup	Tissue Adhesive	SWC	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95 Cl
Pediatric (<18)					
Barnett 1998	7/35	6/30		5.3 %	1.00 [ 0.38, 2.65 ]
Subtotal (95% CI)	35	30	-	5.3 %	1.00 [ 0.38, 2.65 ]
Total events: 7 (Tissue Adhes	ive), 6 (SWC)				
Heterogeneity: not applicable	;				
Test for overall effect: $Z = 0.0$	) (P = 1.0)				
2 Adult (=>18)					
Quinn 1998a	36/50	41/55	-	94.7 %	0.97 [ 0.77, 1.22 ]
Subtotal (95% CI)	50	55	•	<b>94.</b> 7 %	0.97 [ 0.77, 1.22 ]
Total events: 36 (Tissue Adhe	esive), 41 (SWC)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.2$	29 (P = 0.77)				
Total (95% CI)	85	85	•	100.0 %	0.97 [ 0.77, 1.21 ]
Total events: 43 (Tissue Adhe	esive), 47 (SWC)				
Heterogeneity: $Tau^2 = 0.0$ ; Cl	$hi^2 = 0.01, df = 1 (P = 0.94)$	); I <sup>2</sup> =0.0%			
Test for overall effect: $Z = 0.2$	29 (P = 0.78)				
	· · ·				

0.05 0.2 1 5 20 Favours SWC Favours Tiss Adh

Tissue adhesives for traumatic lacerations in children and adults (Review) Copyright  $\ensuremath{\textcircled{\texttt{C}}}$  2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Analysis 1.12. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 12 Cosmesis (WES, Other) at 9 to 12 months by age.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 12 Cosmesis (WES, Other) at 9 to 12 months by age

Study or subgroup	Tissue Adhesive	SWC	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95% Cl
Pediatric (<18)					
Barnett 1998	16/31	14/32		23.8 %	1.18 [ 0.70, 1.98 ]
Subtotal (95% CI)	31	32	-	23.8 %	1.18 [ 0.70, 1.98 ]
Total events: 16 (Tissue Adhe	esive), 14 (SWC)				
Heterogeneity: not applicable	2				
Test for overall effect: $Z = 0.6$	62 (P = 0.53)				
2 Adult (=>18)					
Quinn 1998a	27/37	27/40		76.2 %	1.08 [ 0.81, 1.45 ]
Subtotal (95% CI)	37	40	•	76.2 %	1.08 [ 0.81, 1.45 ]
Total events: 27 (Tissue Adhe	esive), 27 (SWC)				
Heterogeneity: not applicable	2				
Test for overall effect: $Z = 0.5$	53 (P = 0.60)				
Total (95% CI)	68	72	•	100.0 %	1.10 [ 0.86, 1.42 ]
Total events: 43 (Tissue Adhe	esive), 41 (SWC)				
Heterogeneity: Tau <sup>2</sup> = 0.0; C	$hi^2 = 0.09$ , $df = 1$ (P = 0.77)	); I <sup>2</sup> =0.0%			
Test for overall effect: $Z = 0.7$	76 (P = 0.45)				
			0.2 0.5 1 2 5		

Favours SWC Favours Tiss Adh

### Analysis 1.14. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 14 Cosmesis (CVAS) at 1 to 3 months by location.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 14 Cosmesis (CVAS) at 1 to 3 months by location

Study or subgroup	Tissue Adhesive		SWC		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	-	IV,Random,95% CI
I Face							
Quinn 1993	37	60.6 (20.15)	38	57.2 (20.15)		47.9 %	3.40 [ -5.72, 12.52 ]
Zempsky 2001	45	56.2 (18)	41	62.8 (20.5)		52.1 %	-6.60 [ -14.79, 1.59 ]
<b>Subtotal (95% CI)</b> Heterogeneity: $Tau^2 = 30$ Test for overall effect: Z =	0.45; Chi <sup>2</sup> = 2.56, df =	=   (P = 0.  );   <sup>2</sup>	<b>79</b> =61%			100.0 %	-1.81 [ -11.60, 7.98 ]
2 Body	0.00 (1 0.72)						
Subtotal (95% CI) Heterogeneity: not applic Test for overall effect: not	cable		0			0.0 %	0.0 [ 0.0, 0.0 ]
					-20 -10 0 10 Favours SWC Favours Ti	20 ss Adh	

## Analysis 1.15. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 15 Cosmesis (CVAS) at 9 to 12 months by location.

Review: Tiss	sue adhesives for traumatic lacerations in children and adults
Comparison:	I Tissue Adhesive versus Standard Wound Closure

Outcome: 15 Cosmesis (CVAS) at 9 to 12 months by location

Study or subgroup	Tissue Adhesive		SWC		Dif	Mean ference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Ranc	lom,95% Cl	IV,Random,95% Cl
l Face Holger 2004	27	81.54 (19.22)	57	81.88 (15.53)		•	-0.34 [ -8.64, 7.96 ]
2 Body							
					10 5		
					-10 -5 Favours SWC	0 5 10 Favours Tiss Adh	
Tissue adhesives for Copyright © 2009 T			•	,			35

# Analysis 1.16. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 16 Cosmesis (WES, Other) at 5 to 14 days by location.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 16 Cosmesis (WES, Other) at 5 to 14 days by location

Study or subgroup	Tissue Adhesive	SWC	Risk Ratio M- H,Random,95% Cl	Risk Ratio M- H Pandam 95%
	n/N	n/N	H,Random,95%	H,Random,95% Cl
I Face				
Schultz 1979	40/44	42/45		0.97 [ 0.86, 1.10 ]
2 Body				
			0.5 0.7   1.5 2	
			Favours SWC Favours Tiss Adl	1

### Analysis 1.17. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 17 Cosmesis (WES, Other) at I to 3 months by location.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 17 Cosmesis (WES, Other) at 1 to 3 months by location

Risk Rati M-H,Fixed,95% (	Weight	Risk Ratio M-H,Fixed,95% Cl	sWC n/N	Tissue Adhesive n/N	Study or subgroup
					l Face
1.13 [ 0.64, 1.99	21.0 %		/24	4/27	Barnett 1998
1.00 [ 0.91, 1.10	72.9 %	-	41/43	40/42	Schultz 1979
1.03 [ 0.88, 1.20	93.8 %	•	67	69	Subtotal (95% CI)
				esive), 52 (SWC)	Total events: 54 (Tissue Adhe
				$f =   (P = 0.49);  ^2 = 0.0\%$	Heterogeneity: $Chi^2 = 0.48$ , d
				36 (P = 0.72)	Test for overall effect: Z = 0.3
					2 Body
1.50 [ 0.61, 3.67	6.2 %		3/6	6/8	Barnett 1998
1.50 [ 0.61, 3.67	6.2 %	-	6	8	Subtotal (95% CI)
				ive), 3 (SWC)	Total events: 6 (Tissue Adhesi
					Heterogeneity: not applicable
				39 (P = 0.37)	Test for overall effect: Z = 0.8
1.06 [ 0.91, 1.23	100.0 %	•	73	77	Total (95% CI)
				esive), 55 (SWC)	Total events: 60 (Tissue Adhe
				ff = 2 (P = 0.36); I <sup>2</sup> =2%	Heterogeneity: Chi <sup>2</sup> = 2.04, d
				71 (P = 0.48)	Test for overall effect: $Z = 0.7$

0.1 0.2 0.5 1 2 5 10 Favours SWC Favours Tiss Adh

### Analysis 1.18. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 18 Cosmesis (WES, Other) at 9 to 12 months by location.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 18 Cosmesis (WES, Other) at 9 to 12 months by location

Study or subgroup	Tissue Adhesive	SWC	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95% Cl
Face					
Barnett 1998	21/25	24/30	-	77.1 %	1.05 [ 0.82, 1.34 ]
Subtotal (95% CI)	25	30	+	77.1 %	1.05 [ 0.82, 1.34 ]
Total events: 21 (Tissue Adhe	esive), 24 (SWC)				
Heterogeneity: not applicable	2				
Test for overall effect: $Z = 0.1$	39 (P = 0.70)				
2 Body					
Barnett 1998	5/6	0/2		22.9 %	4.71 [ 0.36, 60.97 ]
Subtotal (95% CI)	6	2		22.9 %	4.71 [ 0.36, 60.97 ]
Total events: 5 (Tissue Adhes	sive), 0 (SWC)				
Heterogeneity: not applicable	2				
Test for overall effect: $Z = I$ .	19 (P = 0.24)				
Total (95% CI)	31	32	-	100.0 %	1.48 [ 0.35, 6.35 ]
Total events: 26 (Tissue Adhe	esive), 24 (SWC)				
Heterogeneity: $Tau^2 = 0.70;$	$Chi^2 = 1.81, df = 1 (P = 0.$	18); I <sup>2</sup> =45%			
Test for overall effect: $Z = 0.1$	53 (P = 0.60)				

0.001 0.01 0.1 1 10 100 1000

Favours SWC Favours Tiss Adh

Tissue adhesives for traumatic lacerations in children and adults (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

### Analysis 1.20. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 20 Cosmesis (CVAS) at I to 3 months by deep sutures.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 20 Cosmesis (CVAS) at 1 to 3 months by deep sutures

Study or subgroup	Tissue Adhesive		SWC		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	-	IV,Random,95% CI
I No Deep Sutures							
Quinn 1993	37	60.6 (20.15)	38	57.2 (20.15)		47.9 %	3.40 [ -5.72, 12.52 ]
Zempsky 2001	45	56.2 (18)	41	62.8 (20.5)		52.1 %	-6.60 [ -14.79, 1.59 ]
Subtotal (95% CI)	82		79			100.0 %	-1.81 [ -11.60, 7.98 ]
Heterogeneity: $Tau^2 = 30.4$	15; Chi <sup>2</sup> = 2.56, df :	=   (P = 0.  );   <sup>2</sup>	=61%				
Test for overall effect: $Z = 0$	0.36 (P = 0.72)						
2 Deep Sutures							
Subtotal (95% CI)	0		0			0.0 %	0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicat	ole						
Test for overall effect: not a	applicable						
					-20 -10 0 10	20	

Favours SWC

Favours Tiss Adh

### Analysis 1.21. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 21 Cosmesis (CVAS) at 9 to 12 months by deep sutures.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 21 Cosmesis (CVAS) at 9 to 12 months by deep sutures

Study or subgroup	Tissue Adhesive		SWC		Mean Difference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl	IV,Random,95% Cl
I No Deep Sutures						
Holger 2004	20	79.87 (20.58)	39	83.03 (15.54)		-3.16[-13.41, 7.09]
Mattick 2002a	19	87 (19.6)	25	87 (14.3)		0.0 [ -10.44, 10.44 ]
Subtotal (95% CI)	39		64		-	-1.61 [ -8.93, 5.71 ]
Heterogeneity: $Tau^2 = 0.0$ ; C	Chi <sup>2</sup> = 0.18, df = 1 (P	= 0.67); l <sup>2</sup> =0.0%				
Test for overall effect: $Z = 0$ .	43 (P = 0.67)					
2 Deep Sutures						
Holger 2004	I	79.33 (0)	12	80.06 (17.1)		0.0 [ 0.0, 0.0 ]
Subtotal (95% CI)	1		12			0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable	e					
Test for overall effect: $Z = 0$ .	0 (P < 0.00001)					
Total (95% CI)	40		76			-1.61 [ -8.93, 5.71 ]
Heterogeneity: $Tau^2 = 0.0$ ; C	$Chi^2 = 0.18, df = 1 (P$	= 0.67); l <sup>2</sup> =0.0%				
Test for overall effect: $Z = 0$ .	.43 (P = 0.67)					
					-20 -10 0 10 2	.0

Favours SWC Favours Tiss Adh

### Analysis 1.23. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 23 Cosmesis (WES, Other) at I to 3 months by deep sutures.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 23 Cosmesis (WES, Other) at 1 to 3 months by deep sutures

Study or subgroup	Tissue Adhesive	SWC	Risk Ratio M-	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl	H,Random,95% Cl
I No Deep Sutures				
Barnett 1998	7/35	6/30		1.00 [ 0.38, 2.65 ]
2 Deep Sutures				
			0.1 0.2 0.5 1 2 5 10	
			Favours SWC Favours Tiss Adh	

### Analysis 1.24. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 24 Cosmesis (WES, Other) at 9 to 12 months by deep sutures.

M- H,Random,95% H,R   n/N n/N CI	Risk Ratio M-
Study or subgroup Tissue Adhesive SWC Risk Ratio R M- H,Random,95% H,R I No Deep Sutures	M-
M- H,Random,95% H,R n/N n/N Cl	M-
n/N n/N Cl	Random,95%
	Cl
Barnett 1998 16/31 14/32 1.18 [ 0.7	70, 1.98]
2 Deep Sutures	
0.1 0.2 0.5 1 2 5 10	
Favours SWC Favours Tiss Adh	

### Analysis 1.25. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 25 Cosmesis (CVAS) at 5 to 14 days by tissue adhesive.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 25 Cosmesis (CVAS) at 5 to 14 days by tissue adhesive

Study or subgroup	Treatment		SWC		Di	Mean fference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fiz	«ed,95% Cl	IV,Fixed,95% CI
I BCA Goktas 2002	24	79.17 (8.8)	28	79.17 (8.81)			0.0 [ -4.80, 4.80 ]
2 OCA							
					-10 -5 Favours treatment	0 5 IO Favours control	

### Analysis 1.26. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 26 Cosmesis (CVAS) at I to 3 months by tissue adhesive.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 26 Cosmesis (CVAS) at I to 3 months by tissue adhesive

Study or subgroup	Tissue Adhesive		SWC		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
I BCA							
Goktas 2002	24	81.25 (13.29)	28	74.64 (12.01)		16.9 %	6.61 [ -0.32, 13.54 ]
Quinn 1993	37	60.6 (20.15)	38	57.2 (20.15)	<b>-</b>	13.4 %	3.40 [ -5.72,   2.52 ]
Simon 1997	30	51.5 (20.76)	25	36.5 (21.12)		10.9 %	5.00 [ 3.88, 26.12 ]
<b>Subtotal (95% CI)</b> Heterogeneity: Tau <sup>2</sup> = 6.0 Test for overall effect: Z =	00; Chi <sup>2</sup> = 2.58, df =	2 (P = 0.28); I <sup>2</sup>	<b>91</b> =23%		-	41.2 %	7.50 [ 1.75, 13.25 ]
2 OCA							
Singer 1998	61	83.8 (19.4)	55	82.5 (17.6)		17.3 %	1.30 [ -5.43, 8.03 ]
					-20 -10 0 10 20 Favours SWC Favours Tiss /		(Continued)
Tissue adhesives for tra Copyright © 2009 The				• •	Sons, Ltd.		42

							( Continued)
Study or subgroup	Tissue Adhesive		SWC		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
Bruns 1998	35	68 (29.84)	32	75 (28.43)		8.1 %	-7.00 [ -20.96, 6.96 ]
Quinn 1998a	50	67 (15.22)	48	68.4 (15.22)		18.5 %	-1.40 [ -7.43, 4.63 ]
Zempsky 2001	45	56.2 (18)	41	62.8 (20.5)		14.8 %	-6.60 [ -14.79, 1.59 ]
Subtotal (95% CI)	191		176		•	<b>58.8</b> %	-2.07 [ -5.86, 1.72 ]
Heterogeneity: $Tau^2 = 0.0$	0; Chi <sup>2</sup> = 2.67, df = 3	$(P = 0.45); I^2 = 0.45)$	0.0%				
Test for overall effect: Z =	= 1.07 (P = 0.28)						
Total (95% CI)	282		267		-	100.0 %	1.62 [ -3.17, 6.41 ]
Heterogeneity: $Tau^2 = 22$	2.79; Chi <sup>2</sup> = 13.99, df	= 6 (P = 0.03); I	2 =57%				
Test for overall effect: Z =	= 0.66 (P = 0.51)						
						1	

Analysis I.27. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 27 Cosmesis (CVS) at 9 to 12 months by tissue adhesive.

-20 -10

Favours SWC

0

10 20

Favours Tiss Adh

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 27 Cosmesis (CVS) at 9 to 12 months by tissue adhesive

Study or subgroup	Tissue Adhesive		SWC		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
I BCA							
Simon 1997	17	54.5 (19.6)	15	44 (14.3)		15.1 %	10.50 [ -1.30, 22.30 ]
Subtotal (95% CI)	17		15			15.1 %	10.50 [ -1.30, 22.30 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 1.74 (P = 0.081)						
2 OCA							
Holger 2004	27	81.54 (19.22)	57	81.88 (15.53)		30.5 %	-0.34 [ -8.64, 7.96 ]
Mattick 2002a	19	87 (19.6)	25	87 (14.3)		19.2 %	0.0 [ -10.44, 10.44 ]
Quinn 1998a	37	69 (19.6)	40	69 (14.3)		35.2 %	0.0 [ -7.72, 7.72 ]
Subtotal (95% CI)	83		122		-	<b>84.9</b> %	-0.12 [ -5.09, 4.85 ]
					-20 -10 0 10 20	)	
						-	

Favours treatment Favours control

(Continued . . . )

Tissue adhesives for traumatic lacerations in children and adults (Review) Copyright  $\textcircled{\sc 0}$  2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 43



### Analysis 1.28. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 28 Cosmesis (WES, Other) at 5 to 14 days by tissue adhesive.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 28 Cosmesis (WES, Other) at 5 to 14 days by tissue adhesive

Study or subgroup	Tissue Adhesive n/N	SWC n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% Cl
I BCA					
Schultz 1979	40/44	42/45		29.7 %	0.71 [ 0.15, 3.39 ]
Subtotal (95% CI)	44	45		29.7 %	0.71 [ 0.15, 3.39 ]
Total events: 40 (Tissue Adhe	esive), 42 (SWC)				
Heterogeneity: not applicable	2				
Test for overall effect: $Z = 0.4$	42 (P = 0.67)				
2 OCA					
Quinn 1998a	42/53	43/53		70.3 %	0.89 [ 0.34, 2.31 ]
Subtotal (95% CI)	53	53		70.3 %	0.89 [ 0.34, 2.31 ]
Total events: 42 (Tissue Adhe	esive), 43 (SWC)				
Heterogeneity: not applicable	2				
Test for overall effect: $Z = 0.2$	24 (P = 0.81)				
Total (95% CI)	97	98	-	100.0 %	0.84 [ 0.37, 1.89 ]
Total events: 82 (Tissue Adhe	esive), 85 (SWC)				
Heterogeneity: $Chi^2 = 0.05$ , o	df =   (P = 0.82); $ ^2 = 0.0\%$				
Test for overall effect: $Z = 0.4$	43 (P = 0.67)				
			0.05 0.2 5	20	
			Favours treatment Favours		

### Analysis 1.29. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 29 Cosmesis (WES, Other) at I to 3 months by tissue adhesive.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 29 Cosmesis (WES, Other) at 1 to 3 months by tissue adhesive

Study or subgroup	Tissue Adhesive	SWC	Odds Ratio	Weight	Odds Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
I BCA					
Barnett 1998	20/35	15/30		23.3 %	1.33 [ 0.50, 3.55 ]
Schultz 1979	40/42	41/43		6.5 %	0.98 [ 0.13, 7.27 ]
Subtotal (95% CI)	77	73	-	29.7 %	1.26 [ 0.52, 3.03 ]
Total events: 60 (Tissue Adhe	esive), 56 (SWC)				
Heterogeneity: $Chi^2 = 0.08$ , o	$f = 1 (P = 0.78); I^2 = 0.0\%$				
Test for overall effect: $Z = 0.5$	51 (P = 0.61)				
2 OCA					
Quinn 1998a	36/50	36/48		34.6 %	0.86 [ 0.35, 2.11 ]
Singer 1998	47/61	44/55		35.7 %	0.84 [ 0.34, 2.04 ]
Subtotal (95% CI)	111	103	-	70.3 %	0.85 [ 0.45, 1.60 ]
Total events: 83 (Tissue Adhe	esive), 80 (SWC)				
Heterogeneity: Chi <sup>2</sup> = 0.00, d	$f = 1 (P = 0.97); I^2 = 0.0\%$				
Test for overall effect: $Z = 0.5$	51 (P = 0.61)				
Total (95% CI)	188	176	+	100.0 %	0.97 [ 0.58, 1.62 ]
Total events: 143 (Tissue Adh	nesive), 136 (SWC)				
Heterogeneity: $Chi^2 = 0.58$ , o	$f = 3 (P = 0.90); I^2 = 0.0\%$				
Test for overall effect: $Z = 0$ .	2 (P = 0.90)				
			0.05 0.2 1 5 20		
			Favours treatment Favours control		

### Analysis 1.30. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 30 Cosmesis (WES, Other) at 9 to 12 months by tissue adhesive.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 30 Cosmesis (WES, Other) at 9 to 12 months by tissue adhesive

36.1 % 1.46 [ 0.41, 5.20 ]				
36.1 % 1.46 [ 0.41, 5.20 ]				I BCA
		25/32	26/31	Barnett 1998
36.1 % 1.46 [ 0.41, 5.20 ]	-	32	31	Subtotal (95% CI)
			sive), 25 (SWC)	Total events: 26 (Tissue Adhesi
				Heterogeneity: not applicable
			8 (P = 0.56)	Test for overall effect: Z = 0.58
				2 OCA
63.9 % 1.30 [ 0.49, 3.47 ]		27/40	27/37	Quinn 1998a
63.9 % 1.30 [ 0.49, 3.47 ]	-	40	37	Subtotal (95% CI)
			sive), 27 (SWC)	Total events: 27 (Tissue Adhesi
				Heterogeneity: not applicable
			2 (P = 0.60)	Test for overall effect: Z = 0.52
100.0 % 1.36 [ 0.62, 2.95 ]	-	72	68	Total (95% CI)
			sive), 52 (SWC)	Total events: 53 (Tissue Adhesi
			$f = 1 (P = 0.89); I^2 = 0.0\%$	Heterogeneity: Chi <sup>2</sup> = 0.02, df
			7 (P = 0.44)	Test for overall effect: Z = 0.77

0.05 0.2 I 5 20 Favours treatment Favours control

# Analysis 1.31. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 31 Pain (VAS).

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 31 Pain (VAS)

Study or subgroup	Tissue Adhesive N	Mean(SD)	swc N	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% CI
I Patient							· · /
Quinn 1998a	68	7.2 (18.72)	68	18 (18.72)		100.0 %	-10.80 [ -17.09, -4.51 ]
<b>Subtotal (95% CI)</b> Heterogeneity: not applica Test for overall effect: Z =		)	68		•	100.0 %	-10.80 [ -17.09, -4.51 ]
2 Parent	· · · · · ·						
Bruns 1998	42	9 (51.34)	43	25 (40.62)		8.5 %	-16.00 [ -35.71, 3.71 ]
Simon 1997	30	8 (34.68)	31	29 (33.18)		11.4 %	-21.00 [ -38.04, -3.96 ]
Barnett 1998	83	26 (23.7)	80	39.3 (28.9)		49.9 %	-13.30 [ -21.43, -5.17 ]
Quinn 1993	41	24.7 (32.39)	40	43.7 (32.39)		16.6 %	-19.00 [ -33.11, -4.89 ]
Mattick 2002a	19	5 (23.7)	25	4 (28.9)	_	13.6 %	1.00 [ -14.55, 16.55 ]
Subtotal (95% CI) Heterogeneity: $Tau^2 = 9.1$ Test for overall effect: Z = 3 Doctor			<b>219</b> = 15%		•	100.0 %	-13.42 [ -19.99, -6.85 ]
Barnett 1998	83	22.4 (22.4)	80	35 (26)	-	100.0 %	-12.60 [ -20.06, -5.14 ]
Subtotal (95% CI) Heterogeneity: not applica Test for overall effect: Z = 4 Nurse/Other Observer Barnett 1998	= 3.31 (P = 0.00093)	18.7 (21.8)	<b>80</b> 80	33.6 (27.3)	•	100.0 %	-12.60 [ -20.06, -5.14 ] -14.90 [ -22.50, -7.30 ]
<b>Subtotal (95% CI)</b> Heterogeneity: not applica Test for overall effect: Z =		)	80		•	100.0 %	-14.90 [ -22.50, -7.30 ]
				-50 Favou	) -25 0 25 rs Tiss Adh Favours SW	50 /C	

Tissue adhesives for traumatic lacerations in children and adults (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# Analysis 1.32. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 32 Time to Complete (min).

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 32 Time to Complete (min)

Study or subgroup	Tissue Adhesive		SWC		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
Bruns 1998	42	2.9 (0.96)	43	5.8 (5.69)	-	21.8 %	-2.90 [ -4.63, -1.17 ]
Quinn 1993	41	7.9 ( 3. 3)	40	15.6 (13.13)	<b>_</b>	10.9 %	-7.70 [ -13.42, -1.98 ]
Quinn 1998a	68	3.6 (15.22)	68	12.4 (15.22)	_ <b>_</b>	12.3 %	-8.80 [ -13.92, -3.68 ]
Simon 1997	30	7 (10.91)	31	17 (11.28)		11.3 %	-10.00 [ -15.57, -4.43 ]
Singer 1998	63	5.98 (6.4)	61	10.02 (6.9)	-	20.1 %	-4.04 [ -6.38, -1.70 ]
Zempsky 2001	49	3 (1.9)	48	3.7 (2.1)	-	23.6 %	-0.70 [ -1.50, 0.10 ]
Total (95% CI)	293		291		•	100.0 %	-4.66 [ -7.22, -2.10 ]
Heterogeneity: Tau <sup>2</sup> =	= 7.04; Chi <sup>2</sup> = 31.89,	df = 5 (P<0.0000	);   <sup>2</sup> =84	1%			
Test for overall effect:	Z = 3.57 (P = 0.000)	35)					

-20 -10 0 10 20

Favours Tiss Adh Favours SWC

# Analysis 1.33. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 33 Ease of Procedure (VAS).

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 33 Ease of Procedure (VAS)

Study or subgroup	Tissue Adhesive		SWC		C	Mean Difference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Ra	ndom,95% Cl	IV,Random,95% CI
Mattick 2002a	19	9 (0)	25	5 (0)			0.0 [ 0.0, 0.0 ]
						_	
					-50 -25	0 25	50
					Favours Tiss Adh	Favours SW	VC
	traumatic lacerations he Cochrane Collabor		•	,			48

### Analysis 1.34. Comparison I Tissue Adhesive versus Standard Wound Closure, Outcome 34 Complications.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: I Tissue Adhesive versus Standard Wound Closure

Outcome: 34 Complications

Study or subgroup	Tissue Adhesive	SWC	Risk Difference	Weight	Risk Difference
	n/N	n/N	M- H,Random,95% Cl		-M- H,Random,9 Cl
I Dehiscence					
Barnett 1998	9/62	4/49	+	4.3 %	0.06 [ -0.05, 0.18 ]
Bruns 1998	0/42	0/43	+	28.9 %	0.0 [ -0.04, 0.04 ]
Holger 2004	1/37	0/70		13.8 %	0.03 [ -0.04, 0.09 ]
Quinn 1993	3/37	2/38	_ <del></del>	4.5 %	0.03 [ -0.08, 0.14 ]
Quinn 1998a	3/68	1/68	-	18.1 %	0.03 [ -0.03, 0.09 ]
Simon 1997	1/30	1/31	-	7.3 %	0.00 [ -0.09, 0.09 ]
Singer 1998	2/57	0/57	-	17.6 %	0.04 [ -0.02, 0.09 ]
Zempsky 2001	6/48	1/45		5.5 %	0.10 [ 0.00, 0.21 ]
Subtotal (95% CI)	381	401	•	100.0 %	0.02 [ 0.00, 0.05 ]
Barnett 1998	0/62	2/49		8.6 %	-0.04 [ -0.1 I, 0.02 ]
Test for overall effect: Z = 2. 2 Infection	03 (F - 0.042)				
Bruns 1998	1/42	0/43		8.9 %	0.02 [ -0.04, 0.09 ]
Goktas 2002	0/24	0/28		6.8 %	0.0 [ -0.07, 0.07 ]
Holger 2004	0/37	1/70	+	14.7 %	-0.01 [ -0.06, 0.04 ]
Quinn 1993	1/37	1/38	+	6.7 %	0.00 [ -0.07, 0.07 ]
Quinn 1998a	0/68	1/68	+	22.5 %	-0.01 [ -0.05, 0.03 ]
Simon 1997	1/30	0/31	+	4.7 %	0.03 [ -0.05, 0.12 ]
SIMON 1997				16.0 %	0.02 [ -0.03, 0.06 ]
Singer 1998	1/57	0/57			L · J
	1/57	0/57 0/45	+	11.1 %	0.02 [ -0.04, 0.08 ]
Singer 1998				11.1 % <b>100.0 %</b>	

-0.5 -0.25 0 0.25 0.5

Favours Tiss Adh Favours SWC

(Continued ...)

Study or subgroup	Tissue Adhesive n/N	SWC n/N	Risk Difference H,Random,95% Cl	Weight	Risk Difference H,Random,95% CI
3 Erythema	11/14	11/15			CI
Barnett 1998	14/62	18/49	<b>—•·</b>	29.7 %	-0.14 [ -0.31, 0.03 ]
Quinn 1993	1/37	4/38		70.3 %	-0.08 [ -0.19, 0.03 ]
Subtotal (95% CI)	99	87	•	100.0 %	-0.10 [ -0.19, 0.00 ]
Total events: 15 (Tissue Adhesive),	22 (SWC)				
Heterogeneity: $Tau^2 = 0.0$ ; $Chi^2 =$	0.53, df = 1 (P = 0.4)	7); I <sup>2</sup> =0.0%			
Test for overall effect: $Z = 2.05$ (P	= 0.041)				
4 Delayed closure					
Quinn 1998a	0/68	0/68	-	100.0 %	0.0 [ -0.03, 0.03 ]
Subtotal (95% CI)	68	68	+	100.0 %	0.0 [ -0.03, 0.03 ]
Total events: 0 (Tissue Adhesive), 0	D (SWC)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.0$ (P =	= 1.0)				
5 Discharge					
Barnett 1998	9/62	4/49	-	100.0 %	0.06 [ -0.05, 0.18 ]
Subtotal (95% CI)	62	49	-	100.0 %	0.06 [ -0.05, 0.18 ]
Total events: 9 (Tissue Adhesive), 4	4 (SWC)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.07$ (P	= 0.29)				
			-0.5 -0.25 0 0.25 0.5		
			Favours Tiss Adh Favours SWC		

# Analysis 2.1. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome I Cosmesis (CVAS) at I to 3 months.

Review: Tissue adhesives for traumatic lacerations in children	1 and adults
--	--------------

Comparison: 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond)

Outcome: I Cosmesis (CVAS) at I to 3 months

Study or subgroup	BCA		OCA		Diff	Mean erence	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Rand	om,95% Cl	IV,Random,95% CI
Osmond 1999a	39	70 (13.26)	44	67.5 (14.99)	_		2.50 [ -3.58, 8.58 ]
					-20 -10 Favours OCA	0 10 20 Favours BCA	

Tissue adhesives for traumatic lacerations in children and adults (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

(... Continued)

# Analysis 2.2. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 2 Cosmesis (WES, Other) at 5 to 14 days.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond)

Outcome: 2 Cosmesis (WES, Other) at 5 to 14 days

BCA	OCA	Risk Ratio M-	Risk Ratio M-
n/N	n/N	H,Random,95% Cl	H,Random,95% Cl
30/34	29/36		1.10 [ 0.89, 1.34 ]
		0.2 0.5 2 5	
		Favours OCA Favours BCA	
			n/N n/N H,Random,95% Cl 30/34 29/36

# Analysis 2.3. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 3 Cosmesis (WES, Other) at 1 to 3 months.

Review: Tissue adhesives fo	or traumatic lacerations in ch	ildren and adults		
Comparison: 2 BCA (butyl	cyanoacrylate - Histoacryl) v	versus OCA (octylcyanoacr	ylate - Dermabond)	
Outcome: 3 Cosmesis (WI	ES, Other) at I to 3 months			
Study or subgroup	BCA	OCA	Risk Ratio M- H,Random,95%	Risk Ratio M- H,Random,95%
	n/N	n/N	CI	CI
Osmond 1999a	29/39	35/44		0.93 [ 0.74, 1.19 ]
			0.2 0.5 2 5	
			Favours OCA Favours BCA	

# Analysis 2.4. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 4 Pain (VAS).

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond)

Outcome: 4 Pain (VAS)

Study or subgroup	BCA		OCA		Mean Difference	Weight	Mean Difference
,	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl	Ū.	IV,Random,95% CI
l Patient							
Osmond 1999a	9	25.2 (23.6)	9	8.4 (16.6)		42.0 %	6.80 [ -2.05, 35.65 ]
Subtotal (95% CI)	9		9			42.0 %	16.80 [ -2.05, 35.65 ]
Heterogeneity: not applica	ble						
Test for overall effect: $Z =$	1.75 (P = 0	0.081)					
2 Parent							
Osmond 1999a	36	22.1 (17.1)	36	25.7 (25.4)		58.0 %	-3.60 [ -13.60, 6.40 ]
Subtotal (95% CI)	36		36		-	<b>58.0</b> %	-3.60 [ -13.60, 6.40 ]
Heterogeneity: not applica	ble						
Test for overall effect: $Z =$	0.71 (P=0	0.48)					
3 Doctor							
Subtotal (95% CI)	0		0			0.0 %	0.0 [ 0.0, 0.0 ]
Heterogeneity: not applica							
Test for overall effect: not	applicable						
4 Nurse/Other Observer							
Subtotal (95% CI)	0		0			0.0 %	0.0 [ 0.0, 0.0 ]
Heterogeneity: not applica							
Test for overall effect: not						100.0.0/	
Total (95% CI)	<b>45</b>		<b>45</b>	-720/		100.0 %	4.97 [ -14.76, 24.71 ]
Heterogeneity: $Tau^2 = 148$ Test for overall effect: Z =			= 0.06); 1- =	= 1 2%			
iest for overall effect. Z –	0.47 (r – t	J.6Z)					
					-50 -25 0 25 50	n	
					Favours BCA Favours OC/		
						,	

# Analysis 2.5. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond), Outcome 5 Time to Complete (min).

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond)

Outcome: 5 Time to Complete (min)

Study or subgroup	BCA		OCA		Mean Difference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	IV,Random,95% CI
Osmond 1999a	47	4.2 (3.4)	47	4 (3.2)		0.20 [ -1.13, 1.53 ]
					-10 -5 0 5 10 Favours BCA Favours OCA	

### Analysis 2.6. Comparison 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate -Dermabond), Outcome 6 Complications.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: 2 BCA (butylcyanoacrylate - Histoacryl) versus OCA (octylcyanoacrylate - Dermabond)

Outcome: 6 Complications

Study or subgroup	BCA	OCA	Risk Difference M-	Weight	Risk Difference M-
	n/N	n/N	H,Random,95% Cl		H,Random,95% Cl
I Dehiscence					
Osmond 1999a	2/46	0/47		100.0 %	0.04 [ -0.03, 0.11 ]
Subtotal (95% CI)	46	47	-	100.0 %	0.04 [ -0.03, 0.11 ]
Total events: 2 (BCA), 0 (OCA)					
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.21$ (F	P = 0.23)				
2 Infection					
Osmond 1999a	0/46	0/47		100.0 %	0.0 [ -0.04, 0.04 ]
Subtotal (95% CI)	46	47	+	100.0 %	0.0 [ -0.04, 0.04 ]
Total events: 0 (BCA), 0 (OCA)					
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.0$ (P	= 1.0)				
			-0.2 -0.1 0 0.1 0.2		
			Favours BCA Favours OCA		
					(Continued )

Study or subgroup	BCA	OCA	Risk Difference M- H,Random,95%	Weight	( Continued) Risk Difference M- H,Random,95%
2 En theorem	n/N	n/N	Cl		Cl
3 Erythema Subtotal (95% CI)	0	0		0.0 %	0.0 [ 0.0, 0.0 ]
Total events: 0 (BCA), 0 (OCA)	)				
Heterogeneity: not applicable					
Test for overall effect: not applic	able				
			-0.2 -0.1 0 0.1 0.2		
			Favours BCA Favours OCA		

### Analysis 3.1. Comparison 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV), Outcome I Complications.

Review: Tissue adhesives for traumatic lacerations in children and adults

Comparison: 3 Regular OCA (octylcyanoacrylate - Dermabond) versus High Viscosity OCA (octylcyanoacrylate - Dermabond HV)

Outcome: I Complications

Study or subgroup	Regular OCA	HV OCA		Risk erence M-	Weight	Risk Difference M-
	n/N	n/N	H,Kar	ndom,95% Cl		H,Random,95% Cl
Migration of TA > 1cm						
Singer 2003	32/42	9/42		→	100.0 %	0.55 [ 0.37, 0.73 ]
Subtotal (95% CI)	42	42		-	100.0 %	0.55 [ 0.37, 0.73 ]
Total events: 32 (Regular Ot Heterogeneity: not applicabl Test for overall effect: Z = 6 2 Dehiscence Singer 2003	le	1/36	-	•	100.0 %	-0.03 [ -0.10, 0.04 ]
<b>Subtotal (95% CI)</b> Total events: 0 (Regular OC Heterogeneity: not applicabl Test for overall effect: Z = 0 3 Infection	le	36	•		100.0 %	-0.03 [ -0.10, 0.04 ]
Singer 2003	0/36	0/42	-		100.0 %	0.0 [ -0.05, 0.05 ]
		F	-0.5 -0.25 avours regular OCA	0 0.25 0.5 Favours HV OC,	۹.	(Continued)



## APPENDICES

### Appendix I. Ovid MEDLINE Search Strategy

Ovid MEDLINE was searched using the following strategy in combination with the Cochrane highly sensitive search strategy for identifying reports of randomised controlled trials (Higgins 2005)

- 1 exp Lacerations/ 2 lacerat\$.ti,ab. 3 (traumatic adj (wound\$ or injur\$)).ti,ab.
- 4 or/1-3
- 5 exp Tissue Adhesives/
- 6 exp Acrylates/
- 7 tissue adhesive\$.ti,ab.
- 8 (crylate\$ or bucrylate\$ or cyanoacrylate\$ or enbucrilate\$).ti,ab.
- 9 (glu or glue or glues).ti,ab.
- 10 or/5-9
- 11 4 and 10

## **Appendix 2. Ovid EMBASE Search Strategy**

Ovid EMBASE was searched using the following strategy in combination with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) 1 exp Laceration/

2 lacerat\$.ti,ab. 3 (traumatic adj (wound\$ or injur\$)).ti,ab. 4 or/1-3 5 exp Tissue Adhesive/ 6 exp Acrylic Acid Derivative/ 7 tissue adhesive\$.ti,ab. 8 (crylate\$ or bucrylate\$ or cyanoacrylate\$ or enbucrilate\$).ti,ab. 9 (glu or glue or glues).ti,ab. 10 or/5-9 11 4 and 10

### Appendix 3. Ovid CINAHL Search Strategy

Ovid CINAHL was searched using the following strategy in combination with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) 1 exp "Tears and Lacerations"/ 2 lacerat\$.ti,ab. 3 (traumatic adj (wound\$ or injur\$)).ti,ab. 4 or/1-3 5 exp Fibrin Tissue Adhesive/ 6 tissue adhesive\$.ti,ab. 7 (crylate\$ or bucrylate\$ or cyanoacrylate\$ or enbucrilate\$).ti,ab. 8 (glu or glue or glues).ti,ab. 9 or/5-8 10 4 and 9

### **Appendix 4. Web of Science Search Strategy**

Web of Science - Science Citation Index was searched using the following strategy: #1 TS=(lacerat\* OR skin injur\* OR wound\*) #2 TS=(tissue adhesive\* OR acrylate\* OR cyanoacrylate\* OR octylcyanoacrylate\* OR enbucrilate\* OR bucrylate\* OR glue\* OR suture\*) #3 #1 AND #2 #4 TS=(controlled clinical trial OR meta analysis OR multicenter study OR randomized controlled trial OR random\* OR blind\* OR placebo\*) #5 #3 AND #4

# WHAT'S NEW

Last assessed as up-to-date: 30 September 2007.

Date	Event	Description
9 September 2008	Amended	Converted to new review format.

### HISTORY

Protocol first published: Issue 1, 2002

Review first published: Issue 3, 2002

Date	Event	Description
2 April 2007	New search has been performed	For this second update, new searches were carried out in April 2007. Six studies were identified of which two (Holger 2004, Singer 2003) were included. One additional study identified through the search represents publication of the

Tissue adhesives for traumatic lacerations in children and adults (Review)

 $\textbf{Copyright} @ \textbf{2009 The Cochrane Collaboration. Published by John Wiley \& Sons, Ltd. \\$ 

#### (Continued)

		final results previously included from an abstract (Zempsky 2001). The remaining three studies were excluded. The reviewers' conclusions remain unchanged.
26 May 2004	New search has been performed	A first update was published in the Cochrane Library, Issue 3, 2004 with 11 included studies
2 May 2002	New citation required and conclusions have changed	Substantive amendment. This review was originally pub- lished in the Cochrane Library, Issue 3, 2002 with 9 included studies

# CONTRIBUTIONS OF AUTHORS

Ken Farion (Primary Reviewer): protocol development, study selection, data extraction, data entry, development of final review and updates (original and all updates).

Ellen Crumley: literature searching, quality assessment (original and 1st update).

Lisa Hartling: protocol development, quality assessment, methodological expertise, development of final review and updates (original and all updates).

Terry Klassen: protocol development, content and methodological expertise, development of final review and updates (original and all updates).

Martin Osmond: protocol development, content expertise, development of final review and updates (original and all updates).

Kelly Russell: study selection, data extraction, data entry, development of final review and updates (original and all updates).

Natasha Wiebe: protocol development, statistical analyses, development of final review (original and 1st update).

Tamara Durec: literature searching, development of update (2nd update).

Ben Vandermeer: statistical analyses, development of update (2nd update).

# DECLARATIONS OF INTEREST

Dr. Martin Osmond received funding from Closure Medical Corp. for his study (Osmond 1999a).

### SOURCES OF SUPPORT

### Internal sources

• Alberta Research Centre for Child Health Evidence (ARCHE), University of Alberta, Edmonton, Canada.

### **External sources**

• Alberta Heritage Foundation for Medical Research, Canada.

# INDEX TERMS

### Medical Subject Headings (MeSH)

Lacerations [\*therapy]; Randomized Controlled Trials as Topic; Tissue Adhesives [\*therapeutic use]; Treatment Outcome

## MeSH check words

Adult; Child; Humans